id,collection,Type de document,DOI,PMID,Titre,Auteur(s),Titre de la manifestation scientifique,Organisateur(s) de la manifestation scientifique,Ville,Pays,Date de début de la manifestation scientifique,Titre de l'ouvrage,Titre de la revue,Numéro,Pagination,Éditeur,Date de publication,ISSN,Mot(s)-clé(s),Mot(s)-clé(s) en anglais,Discipline(s) HAL,Résumé,Résumé en anglais,Langue,Article revu par les pairs,Audience,Vulgarisation,Projet ANR
"93322028-8824-4396-b1a5-c30adca35475","20.500.12210/13","Autre communication scientifique (congrès sans actes - poster - séminaire...)||Communication dans un congrès avec actes","10.1016/j.pdpdt.2017.01.042",,"A new flexible and homogeneous device for photodynamic treatment of actinic keratosis","Mordon, Serge||Thecua, E.||Tylcz, J.-B.||Vicentini, C.||Mortier, L.||Szeimies, R.-M.","IPA",,"NANCY","France","2016-10-24",,,,,,"2017-03",,,,"Sciences du Vivant [q-bio]||Sciences du Vivant [q-bio]/Cancer",,,"Anglais","Oui","Internationale","Non",
"6a22685f-5156-482f-bd29-fc80ca58a645","20.500.12210/13","Compte-rendu et recension critique d'ouvrage","10.1016/j.ijpharm.2020.119554",,"A facile fabrication of dissolving microneedles containing 5-aminolevulinic acid","Champeau, Mathilde||Jary, Dorothée||Mortier, Laurent||Mordon, Serge||Vignoud, Séverine",,,,,,,"International Journal of Pharmaceutics","586","119554 -","Elsevier","2020-08-30","0378-5173",,,"Sciences du Vivant [q-bio]",,,"Anglais",,,"Non","Grenoble, une chimie bio-motivée"
"d4a55cbe-d58b-422e-9ef9-3959723bc450","20.500.12210/13","Compte-rendu et recension critique d'ouvrage",,,"ILLUMINATION PROFILE CHARACTERIZATION OF A LIGHT DEVICE FOR THE DOSIMETRY OF INTRA-PLEURAL PHOTODYNAMIC THERAPY FOR MESOTHELIOMA","Munck, Camille||Mordon, Serge||Betrouni, Nacim",,,,,,,"Photodiagnosis and Photodynamic Therapy",,,"Elsevier","2016-09-01","1572-1000",,"Intrapleural photodynamic therapy||dosimetry||illumination profile||light device","Sciences du Vivant [q-bio]/Cancer",,"BACKGROUND: Complete and homogeneous illumination of the pleural cavity is essential to the success of photodynamic therapy (PDT) for mesothelioma, but remains a challenge. Knowing the repartition and propagation of light around the light applicator could be the first step towards optimizing dosimetry. Here we propose a characterization method of the illumination profile of a specific light device.METHODS: The light wand, made of a cylindrical diffuser located inside an endotracheal tube, was fixed in a tank filled with dilute 0.01% intralipid. Light dosimetry was performed around the tip of the wand using two complementary methods: direct measurements of light power with an isotropic probe and measurements of light distribution characterization.RESULTS: Dosimetry with the isotropic probe showed an ellipse-shaped illumination. An optimized effective attenuation coefficient was deduced. Combined with the spatial representation, a theoretical illumination profile was established with iso-surfaces of fluence rate, defining a gradient light dose according to the distance from the diffuser.CONCLUSION: A theoretical illumination profile of a light device was established and could be part of an intra-operative dosimetry system to improve light delivery during intrapleural PDT.Copyright © 2016. Published by Elsevier B.V.","Anglais",,,"Non",
"19a5e39e-9838-40c0-a83a-4810020a5696","20.500.12210/13","Compte-rendu et recension critique d'ouvrage",,,"The conventional protocol versus a protocol including illumination with a fabric-based biophotonic device (the Phosistos protocol) in photodynamic therapy for actinic keratosis: a randomized, controlled, non-inferiority clinical study","Mordon, Serge||Vignion-Dewalle, A||Abi-Rached, H||Thecua, E||Lecomte, F.||Vicentini, C.||Deleporte, P.||Béhal, H.||Kerob, D.||Hommel, T||Duhamel, A||Szeimies, R||Mortier, L",,,,,,,"British Journal of Dermatology",,,"Wiley","2020-01-02","0007-0963",,,"Sciences du Vivant [q-bio]/Cancer||Sciences du Vivant [q-bio]||Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Dermatologie||Sciences du Vivant [q-bio]/Ingénierie biomédicale",,,"Anglais",,,"Non",
"f075cb4c-4448-46a4-be90-b0d49a08996d","20.500.12210/13","Compte-rendu et recension critique d'ouvrage","10.1016/j.pdpdt.2017.02.011","28254624","Real-time light dosimetry for intra-cavity photodynamic therapy: Application for pleural mesothelioma treatment","Betrouni, Nacim||Munck, Camille||Bensoltana, Wael||Baert, Grégory||Dewalle-Vignion, Anne-Sophie||Scherpereel, Arnaud||Mordon, Serge",,,,,,,"Photodiagnosis and Photodynamic Therapy",,"Epub ahead of print","Elsevier","2017-02-22","1572-1000",,"photodynamic therapy||intra-cavity application||light distribution modeling||dosimetry||real time tracking||imaging","Sciences du Vivant [q-bio]",,"Complete and homogeneous illumination of the target is necessary for the success of a photodynamic therapy (PDT) procedure. In most applications, light dosimetry is done using detectors placed at strategic locations of the target. In this study we propose a novel approach based on the combination of light distribution modeling with spatial localization of the light applicator for real time estimation and display of the applied dose on medical images. The feasibility approach is demonstrated for intrapleural PDT of malignant pleural mesothelioma.","Anglais",,,"Non",
"ff41a301-0df4-4369-b804-72ddeab3dc0f","20.500.12210/13","Communication dans un congrès avec actes","10.1016/j.pdpdt.2017.01.078",,"A new display inspired by games to show what you like or don't like in PDT","Anne, Valérie||Boninsegna, C.||Frochot, C.||Goria, Stéphane||Landon, J.||Mordon, Serge||Vicentini, C.","Congress Photodynamic Therapy and Photodiagnosis update","CNRS - Laboratoire Réactions et Génie des Procédés (Céline Frochot)||Institut national de la santé et de la recherche médicale (Inserm) (Serge Mordon)||Université de Lorraine (Muriel Barberi-Heyob)","Nancy","France","2016-10-24","Photodiagnosis and Photodynamic Therapy",,,,"Elsevier","2017-03",,"thérapie photodynamique||Jeu de plateau||Visualisation de données||analyse multidimensionnelle||Analyse multivariée","Game||Photodiagnosis||PDT||Photodynamic Therapy||Display||Multidimensional analysis||Board game||wargame||data visualization||Multivariate analysis","Sciences de l'Homme et Société/Sciences de l'information et de la communication||Sciences du Vivant [q-bio]||Sciences du Vivant [q-bio]/Cancer",,"The data visualization is a research area both old and growing [1–3]. For a long time it has played an important role in decision support [4]. Thus, many techniques have been developed to help identify, sort and analyze information in a decision-making [5]. The potential of games for non-fun activities, including data visualiza-tion, has been neglected for many years. But since the 2000s and the development of serious games [6], new kinds of communica-tion tools such as the advergames [7], newsgames [8] and political games [9] have been proposed. Similarly, another design approach, inspired by the game, outcome areas of Computer Science and Man-agement science, emerged in the mid-2000s. It refers to the idea of a transformation process of activities or tools by an addition of ele-ments used in game design [10,11]. These changes of thought for the design of some communication tools have enabled the develop-ment of new mediums including for data collection. Nevertheless, this kind of information visualization for the purpose of communi-cation in contexts of strategic thinking and scientific and technical information is still little used.","Anglais","Oui","Internationale","Non",
"abcdc62c-c686-4c21-8416-418237121503","20.500.12210/13","Compte-rendu et recension critique d'ouvrage",,,"Photodynamic therapy for actinic keratosis: Is the European consensus protocol for daylight PDT superior to conventional protocol for Aktilite CL 128 PDT?","Vignion-Dewalle, Anne-Sophie||Baert, Grégory||Thecua, Elise||Vicentini, Claire||Mortier, Laurent||Mordon, Serge",,,,,,,"Journal of Photochemistry and Photobiology B: Biology",,,"Elsevier","2017-07-22","1011-1344",,"Photodynamic therapy||local damage comparison||mathematical modeling||red light||daylight||Aktilite CL 128","Sciences du Vivant [q-bio]||Sciences du Vivant [q-bio]/Cancer",,"Background: Topical photodynamic therapy (PDT) is an established treatment modality for various dermato-oncologic conditions. In Europe, initially requiring irradiation with red light, PDT of actinic keratosis (AK) can now also be carried out with exposure to daylight that has been clinically proven to be as effective as and less painful than red light. Objectives: In this paper, we propose a comparison between the conventional protocol for Aktilite CL 128 (red light source) PDT and the European consensus protocol for daylight PDT — with the exposure is assumed to be performed during either a clear sunny day or an overcast day — in the treatment of AK with methyl aminolevulinate through a mathematical modeling. Method: This already published modeling that is based on an iterative procedure alternating determination of the local fluence rate and updating of the local optical properties enables to estimate the local damage induced by the therapy. Results: The European consensus protocol for daylight PDT during a sunny day and an overcast day provides, on average, 6.50 and 1.79 times higher PDT local damages at the end 2 of the treatment than those obtained using the conventional protocol for Aktilite CL 128 PDT, respectively. Conclusions: Results analysis shows that, even performed during an overcast day, the European consensus protocol for daylight PDT leads to higher PDT local damages than the efficient conventional protocol for Aktilite CL 128.","Anglais",,,"Non",
"9d0c4c4c-b9d2-473d-84b4-f546e02bf5c8","20.500.12210/13","Compte-rendu et recension critique d'ouvrage","10.2196/15026","31793891","Photodynamic Therapy using a new painless Light Emitting Fabrics devise in the treatment of Extramammary Paget disease of the Vulva (the PAGETEX study): protocol for an interventional efficacy and safety trial","Lecomte, Fabienne||Thecua, Elise||Ziane, Laurine||Deleporte, Pascal||Duhamel, Alain||Maire, Cyril||Staumont-Sallé, Delphine||Mordon, Serge||Mortier, Laurent",,,,,,,"Journal of Medical Internet Research","8||12","e15026","JMIR Publications","2019-12","1438-8871",,"extramammary Paget disease of the vulva||light emitting fabrics||methyl aminolevulinate||photodynamic therapy","Sciences du Vivant [q-bio]||Sciences du Vivant [q-bio]/Cancer||Sciences du Vivant [q-bio]/Médecine humaine et pathologie||Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Dermatologie",,"BACKGROUND: Extramammary Paget disease of the vulva (EMPV) is a rare skin disorder commonly seen in postmenopausal Caucasian females that appears clinically as red, eczematous, pruriginous, and sometimes painful lesions. Although most cases are noninvasive, EMPV may be associated with an underlying or distant adenocarcinoma. EMPV has a chronic and relapsing course. The reference treatment is based on local surgical excision with negative margins. However, disease frequently extends far from the visible lesion, and surgical margins are frequently positive. Topical photodynamic therapy (PDT) is an established treatment modality for various dermatooncologic conditions. For example, red light irradiation with the Aktilite CL 128 and Metvixia (Galderma SA) as a photosensitizing molecule is a conventional protocol approved and widely used in Europe for PDT treatment of actinic keratosis, but this treatment is not yet widely used for EMPV because it has never clearly been demonstrated and is very painful.OBJECTIVE: The aim of the study is to investigate the efficacy and safety relating to the medical device PAGETEX as a new painless PDT device using Metvixia in the treatment of vulvar Paget disease. The primary end point is the disease control rate at 3 months in 30% of the patients included, defined as stability, partial response, or total response, considering the extent of the lesion. Secondary end points are the disease control rate at 6 months, patient quality of life, level of pain experienced by the patient at each PDT session, severity of erythema, presence of protoporphyrin IX in Paget cells after each PDT session, and overall satisfaction level of the patient.METHODS: The trial is an interventional, exploratory, simple group, nonrandomized, and single center (Lille University Hospital) study. Twenty-four patients will be included according to Simon's optimal plan. Therapeutic procedure is based on a cycle of two PDT sessions with the PAGETEX medical device at 15-day intervals (Metvixia incubation during 30 minutes and 635 nm red light illumination with a low irradiance for 2 hours and 30 minutes for a total fluence of 12 J/cm²). At the assessment session, 3 months after inclusion, if the control of the disease is partial or null, the patient will complete another cycle of two PDT sessions. A final evaluation will be performed in all patients at 6 months. Analyses will be performed using SAS version 9.4 software (SAS Institute Inc). The characteristics of the patients at baseline will be described; qualitative variables will be described by numbers and percentages, and quantitative variables will be described either by the mean and standard deviation for Gaussian distribution or by the median and interquartile range (ie, 25th and 75th percentiles). The normality of the distributions will be tested by a Shapiro-Wilk test and checked graphically by histograms.RESULTS: First patient was included in September 2019 and clinical investigations are planned until August 2022. The final results of this study are expected to be available in January 2023.CONCLUSIONS: This clinical trial aims to evaluate the efficacy and safety of a new PDT protocol for the treatment of EMPV. The PAGETEX device could become the treatment of choice if it is effective, painless, and easy to implement and use in hospitals.TRIAL REGISTRATION: ClinicalTrials.gov NCT03713203; https://clinicaltrials.gov/ct2/show/NCT03713203.INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/15026.","Anglais",,,"Non",
"efecd16d-d027-4339-98a0-a8618a1d599c","20.500.12210/13","Autre communication scientifique (congrès sans actes - poster - séminaire...)||Communication dans un congrès avec actes","10.1016/j.pdpdt.2017.01.145",,"Treatment of a vulvar Paget disease by photodynamic therapy with a new light emitting fabric based device","Vicentini, C.||Carpentier, O.||Tylcz, J.-B.||Mortier, L.||Betrouni, N.||Mordon, Serge","IPA",,"NANCY","France","2016-10-24",,,,,,"2017-03",,,,"Sciences du Vivant [q-bio]||Sciences du Vivant [q-bio]/Cancer",,,"Anglais","Oui","Internationale","Non",
"f5b4e9ea-a3e9-4a3c-ab11-02d511141afb","20.500.12210/13","Autre communication scientifique (congrès sans actes - poster - séminaire...)||Communication dans un congrès avec actes","10.1016/j.pdpdt.2017.01.048",,"Set-up of the first pilot study on intraopertive 5-ALA PDT: INDYGO trial","Mordon, Serge||Vermandel, M.||Quidet, M.||Lecomte, Fabienne||Lerhun, E.||Betrouni, N.||Reyns, N.||Dupont, Clément","IPA",,"NANCY","France","2016-10-24",,,,,,"2017-03",,,,"Sciences du Vivant [q-bio]||Sciences du Vivant [q-bio]/Cancer",,"University Lille, INSERM, CHU Lille, U1189 – ONCO-THAI – Image Assisted Laser Therapy for Oncology, Lille, France Nowadays, Glioblastoma Multiform (GBM) remains an incurable brain tumour despite of recent advances in the standard of care. Patients harboring newly diagnosed GBM, de novo GBM, undergo to surgery for maximal tumour resection followed by radiation therapy and concomitant and adjuvant chemotherapy (Temozolomide). This protocol has raised the overall survival to 14.5 months. Promising results have been documented concerning 5-ALA interstitial photodynamic therapies. However, interstitial PDT has always been delivered to treat recurrent or non-operable tumours. Because of heterogeneous population of patients with different care protocols in the context of their relapsing disease or the absence of controlled clinical trial, efficacy of 5-ALA PDT is not still evidenced and thus not included in the standard protocol. In order to prove the 5-PDT efficacy on patients harboring de novo GBM, our group has developed a specific medical device to deliver PDT intraoperatively in the surgical cavity. The main idea is to benefit from the course of 5-ALA Fluores-cence Guided Resection (FGR) to achieve an illumination with the suitable wavelength (635 nm). Treatment of the infiltrating cells by a PDT effect is expected in the first millimeters of the surgical cavity. In such manner, intraoperative PDT is a simple add-on to the standard protocol that is more ethically acceptable and more efficient to assess PDT efficacy. Ten patients will be enrolled. Each patient will undergo standard treatment protocol including PDT early after surgery. 25 J/cm 2 will be delivered at 5 mm of the surgical cavity borders. A fractionation scheme will be applied: 5 fractions of 5 J/cm 2 each with off-period of 2 min between each fraction. A first early post-operative MRI will be acquired on the intraoperative MRI of our department. Then, MRI will be acquired quarterly to monitor the treatment response. The primary endpoint is the feasibility of intraoperative PDT, estimated by the proportion of patients who undergone intraoper-ative PDT without unacceptable toxicity. The expected objective is 70%, 7 of 10 patients that we plan to include. Secondary endpoints are progression-free survival (PFS), overall survival, and evaluation at 3 months, 6 months and 12 months of radiation treatment response and patients' quality of life. Finally, after the feasibility and the absence of adverse effects, our protocol will be experienced through a controlled multicenter clinical trial (Phase II) which will focus on dose escalation (light and 5-ALA) and new biomarkers findings. This multicenter clinical trial will be setup and performed with the support of the European network Synaps (http://www. synaps-project.eu).","Anglais","Oui","Internationale","Non",
"847c49c8-4f99-4727-8487-6d795d3ec8ea","20.500.12210/13","Compte-rendu et recension critique d'ouvrage","10.1016/j.jphotobiol.2019.111544","31295716","Photodynamic therapy for skin cancer : How to enhance drug penetration ?","Champeau, Mahilde||Vignoud, Severine||Mortier, Laurent||Mordon, Serge",,,,,,,"Journal of Photochemistry and Photobiology B: Biology","197","111544","Elsevier","2019","1011-1344",,"5-aminolevulinic acid||Drug penetration||Photodynamic therapy||Skin pretreatment||Skin cancer","Sciences du Vivant [q-bio]/Sciences pharmaceutiques/Pharmacologie||Sciences du Vivant [q-bio]/Cancer||Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Dermatologie||Sciences du Vivant [q-bio]/Ingénierie biomédicale||Chimie/Chimie thérapeutique",,"Photodynamic therapy (PDT) induced by protoporphyrin IX (PpIX) has been widely used in dermatological practices such as treatment of skin cancers. Clearance rate depends on different factors such as light irradiation, skin oxygenation and drug penetration. The poor penetration of 5-aminolevulinic acid (5-ALA) with topical application is limited and restrains the production of PpIX which could restrict PDT outcomes. This review will focus on techniques already used to enhance drug penetration in human skin, and will present their results, advantages, and drawbacks. Chemical and physical pretreatments will be discussed. Chemical pre-treatments comprise of drug formulation modification, use of agents that modify the heme cycle, enhance PpIX formation, and the combination of differentiation-promoting agent prior to PDT. On the other hand, physical pretreatments affect the skin barrier by creating holes in the skin or by removing stratum corneum. To promote drug penetration, iontophoresis and temperature modulation are interesting alternative methods. Cellular mechanisms enrolled during chemical or physical pretreatments have been investigated in order to understand how 5-ALA penetrates the skin, why it is preferentially metabolized in PpIX in tumour cells, and how it could be accumulated in deeper skin layers. The objective of this review is to compare clinical trials that use innovative technology to conventional PDT treatment. Most of these pretreatments present good or even better clinical outcomes than usual PDT.","Anglais",,,"Non","Grenoble, une chimie bio-motivée"
"be04fbd2-93da-4338-b41b-0a646306e48a","20.500.12210/13","Autre communication scientifique (congrès sans actes - poster - séminaire...)||Communication dans un congrès avec actes","10.1016/j.pdpdt.2017.01.169",,"Preliminary results on 5-ALA PDT fractionation on a preclinical rodent model","Mordon, Serge||Dupont, Clément||Betrouni, N.||Reyns, N.||Vermandel, M.","IPA",,"NANCY","France","2016-10-24",,,,,,"2017-03",,,,"Sciences du Vivant [q-bio]||Sciences du Vivant [q-bio]/Cancer",,"Glioblastoma Multiform (GBM) is a high-grade brain tumour with local recurrence and poor outcome. Photodynamic therapy to treat glioblastoma has been recently reported to improve overall survival. However, controlled study to evidence treatment efficacy is still expected and treatment delivery has to be optimized. Several parameters might be optimized such as fluence rate, dose escalation or fractionation of light delivery. Specially, fractionation of light delivery is expected to enhance treatment efficiency by restoring tissue oxygenation. Thus, we have evaluated light fractionation on a preclinical rodent model harbouring grafted GBM. Thirty-nine "" Nude "" rats were grafted with human U87 cells. Cells were stereotactically grafted in rat brain. After the presence and the size of the tumour were assessed by microMRI, PDT was delivered interstitially. Light was delivered through an optical fibre introduced into the tumour after PS precursor intake (5-ALA). The rats were randomized in three groups: (1) without illumination, (2) with 2-steps light fractionation and (3) with 5-steps light fraction-ation. Brain immunohistology and microMRI images were achieved to evaluate the treatment effects. On diffusion MRI, elevated diffusion values in tumour centre among treated animals were observed, especially for the 5-steps fractionation group. Perfusion decreased around the treatment site, especially in the 5-steps fractionation group. Histology confirmed our MRI findings, with a more extensive necrosis and apopto-sis associated with a rarefiedangiogenic network in the treatment area, after 5-steps fractionation PDT. However, more surrounding oedema and neovascularization in the peripheral ring after 5-steps fractionation PDT were also noticed. Finally we observed that interstitial PDT induced more tumour necrosis and apoptosis when applying 5-steps fractionation. However , this scheme also led to significant peripheral oedema and neovascularization. Diffusion and perfusion were able to predict the histological lesions. Nevertheless, apoptosis cells death remains the preferred effect in order to decrease potential side effects. We hypothesize a lower fluence rate with the same light fractionation scheme might increase apoptosis while decreasing necrosis and oedema. Preclinical study is still on going to verify this hypothesis. http://dx.","Anglais","Oui","Internationale","Non",
"28b19d03-b7e5-4ce2-9092-9d2308c5c788","20.500.12210/13","Compte-rendu et recension critique d'ouvrage","10.3390/jcm9041185",,"Photodynamic Therapy Using a New Folate Receptor-Targeted Photosensitizer on Peritoneal Ovarian Cancer Cells Induces the Release of Extracellular Vesicles with Immunoactivating Properties","Baydoun, Martha||Moralès, Olivier||Frochot, Céline||Ludovic, Colombeau||Leroux, Bertrand||Thecua, Elise||Ziane, Laurine||Grabarz, Anne||Kumar, Abhishek||De Schutter, Clémentine||Collinet, Pierre||Azais, Henri||Mordon, Serge||Delhem, Nadira",,,,,,,"Journal of clinical medicine","9||4","1185","MDPI","2020","2077-0383",,"photodynamic therapy||folate-coupled photosensitizer||ovarian carcinosis||extracellular vesicles","Sciences du Vivant [q-bio]/Cancer||Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Gynécologie et obstétrique||Sciences du Vivant [q-bio]/Immunologie/Immunothérapie",,"Often discovered at an advanced stage, ovarian cancer progresses to peritoneal carcinoma, which corresponds to the invasion of the serosa by multiple tumor implants. The current treatment is based on the combination of chemotherapy and tumor cytoreduction surgery. Despite the progress and standardization of surgical techniques combined with effective chemotherapy, post-treatment recurrences affect more than 60% of women in remission. Photodynamic therapy (PDT) has been particularly indicated for the treatment of superficial lesions on large surfaces and appears to be a relevant candidate for the treatment of microscopic intraperitoneal lesions and non-visible lesions. However, the impact of this therapy on immune cells remains unclear. Hence, the objective of this study is to validate the efficacy of a new photosensitizer [pyropheophorbide a-polyethylene glycol-folic acid (PS)] on human ovarian cancer cells and to assess the impact of the secretome of PDT-treated cells on human peripheral blood mononuclear cells (PBMC). We show that PS, upon illumination, can induce cell death of different ovarian tumor cells. Furthermore, PDT using this new PS seems to favor activation of the immune response by inducing the secretion of effective cytokines and inhibiting the pro-inflammatory and immunosuppressive ones, as well as releasing extracellular vesicles (EVs) prone to activating immune cells. Finally, we show that PDT can activate CD4+ and CD8+ T cells, resulting in a potential immunostimulating process. The results of this pilot study therefore indicate that PS-PDT treatment may not only be effective in rapidly and directly destroying target tumor cells but also promote the activation of an effective immune response; notably, by EVs. These data thus open up good prospects for the treatment of micrometastases of intraperitoneal ovarian carcinosis which are currently inoperable.","Anglais",,,"Non",
"a0380e1f-d093-407f-9d09-ff32f91e9e87","20.500.12210/13","Compte-rendu et recension critique d'ouvrage","10.2217/fon-2017-0261","28942677","A novel device for intraoperative photodynamic therapy dedicated to glioblastoma treatment","Dupont, Clément||Mordon, Serge||Deleporte, Pascal||Reyns, Nicolas||Vermandel, Maximilien",,,,,,,"Future Oncology",,"Epub ahead of print","Future Medicine","2017-09-25","1479-6694",,"fluoro-guided resection||glioblastoma||instrumentation||intraoperative PDT||medical device||neurosurgery","Sciences du Vivant [q-bio]/Cancer",,"AIM:Photodynamic therapy (PDT) appears to be a valuable new treatment modality for cancer therapy. Studies have reported successful application of PDT for glioblastoma. Here, we introduce a new device dedicated to intraoperative PDT delivered early after fluoro-guided resection combined with a transfer function that determines the treatment time based on the size of the surgical resection cavity.MATERIALS & METHODS:First, we describe the device, which is composed of a trocar, a balloon filled with a diffusing solution, and a fiber guide in which a cylindrical light diffuser is inserted. Ex vivo experiments were performed to measure the fluence rate inside biological tissues. A calibration factor was defined to convert power measurements into fluence rate values. Calf brains were used to simulate light propagation in human brain tissue, and the photosensitizer administration effect on optical properties was discussed. The temperature elevation during illumination was evaluated.RESULTS:Light power was measured in tissues surrounding the device during ex vivo experiments. Using the previously characterized calibration factor, power measurements were converted to fluence rate values to obtain the transfer function. No thermal elevation was observed during a 2-h temperature test, and the impact of protoporphyrin IX on brain optical properties was considered negligible.CONCLUSION:A discussion of experimental precision is presented. The light duration determined by the abacus had a standard deviation of <1 min. This value is weak compared with the total illumination time necessary to treat one patient. The main advantage of our device lies in its straightforward implementation of intraoperative PDT for neurosurgery with acceptable dosimetry and easy treatment time.","Anglais",,,"Non",
"bd5bcf7e-de7e-4a17-9f75-f7d0b18b4d4b","20.500.12210/13","Autre communication scientifique (congrès sans actes - poster - séminaire...)||Communication dans un congrès avec actes","10.1016/j.pdpdt.2017.01.146",,"Photodynamic therapy for actinic keratoses: How effective are two white led light doses compared with two standard light doses?","Mordon, Serge||Vignion-Dewalle, S.||Betrouni, N.||Thecua, E.||Vicentini, C.","IPA",,"NANCY","France","2016-10-24",,,,,,"2017-03",,,,"Sciences du Vivant [q-bio]||Sciences du Vivant [q-bio]/Cancer",,,"Anglais","Oui","Internationale","Non",
"93920700-5bad-4282-9a07-718978d86320","20.500.12210/13","Compte-rendu et recension critique d'ouvrage","10.1002/tbio.202000005",,"Light emitting fabrics for Photodynamic Therapy: technology, experimental and clinical applications","Mordon, Serge||Thecua, Elise||Ziane, Laurine||Lecomte, Fabienne||Deleporte, Pascal||Baert, Grégory||Dewalle-Vignion, Anne-Sophie",,,,,,,"translational biophotonics",,,"Wiley","2020-06-08",,,,"Sciences du Vivant [q-bio]||Sciences du Vivant [q-bio]/Cancer||Sciences du Vivant [q-bio]/Ingénierie biomédicale",,"A homogeneous and reproducible fluence rate delivery during clinical PDT (PhotoDynamic Therapy) plays a determinant role in preventing under-or overtreatment. The development of a flexible light source able to generate uniform light on all its surface would considerably improve the homogeneity of light delivery. The integration of plastic optical fibers into textile structures offers an interesting alternative. This article aims to describe briefly the technology used to develop Light Emitting Fabrics (LEF) and their use in vitro (CELL-LEF), in vivo (VIVO-LEF) for experimental evaluation of PDT. At last, the use of LEF for clinical applications is given by 3 examples. For in-vitro applications, the CELL-LEF device allows the illumination of several 96-well cell culture plates. For the VIVO-LEF, the system developed for PDT can treat 3 mice simultaneously with a homogeneous and high irradiance The medical LEF systems developed for PDT in Dermatology for the treatment of actinic keratosis demonstrate their superiority thanks to a uniform light distribution due the flexibility of LEF. Interestingly, the technology used for manufacturing LEF is very well known by the textile industry, leading to very competitive production costs. The fact that optical fibers can transmit light from 400 nm to 1200 nm allows the connection of LEF to different laser sources covering the light spectrum of all photosensitizers used for medical applications. New developments should allow to use the LEF inside cavities such as the pleural or the peritoneal cavities.","Anglais",,,"Non",
"82cce133-c903-4ccb-975d-0b58db87841b","20.500.12210/13","Communication dans un congrès avec actes","10.1016/j.pdpdt.2017.01.144",,"PHOS-ISTOS: A new flexible and homogeneous device for photodynamic treatment of actinic keratosis, first clinical results","Mordon, Serge||Thecua, E.||Tylcz, J.-B.||Vicentini, C.||Mortier, L.||Szeimies, R.-M.","IPA",,"NANCY","France","2016-10-24",,"Photodiagnosis and Photodynamic Therapy",,,,"2017-03",,,,"Sciences du Vivant [q-bio]||Sciences du Vivant [q-bio]/Cancer",,"The PHOS-ISTOS device (resulting from the European project "" CIP project 621103 PHOSISTOS "") based on light emitting fabric is proposed for the treatment of actinic keratosis. Actinic kerato-sis is common pre-cancerous skin lesions, which mainly affect the elderly population. Induced by sun damages, these lesions are usually present on the scalp, shoulders or arms of the patients and thus are easily reachable by light, making PDT one of the first line treatment [1]. Optical fibers are knitted to build a flexible structure that produces homogeneous light. The fabrics are embedded within an adjustable plastic helmet and illuminated by a fractionated LASER source. The low delivered irradiance (4 mW/cm 2) and the shorter photosensitizer application time ensure a significant pain reduction , compared to discomfort levels usually experienced by patients during a conventional PDT. The proposed device delivers a total light dose of 12 J/cm 2 , instead of 37 J/cm 2 which efficiency is being assessed in a bi-centric clinical trial. The first results of the clinical test (assessment of pain, patient's comfort and PDT action of the device) will be presented.","Anglais","Oui","Internationale","Non",
"bc3144ee-18ba-4661-bddf-1db85dd56279","20.500.12210/13","Compte-rendu et recension critique d'ouvrage",,,"Photodynamic therapy for actinic keratosis of the forehead and scalp: a randomized, controlled, phase II clinical study evaluating the non-inferiority of a new protocol involving irradiation with a light-emitting, fabric-based device (the Flexitheralight protocol) compared with the conventional protocol involving irradiation with the Aktilite CL 128 lamp.","Vicentini, C.||Vignion-Dewalle, Anne-Sophie||Thecua, E||Lecomte, F.||Maire, C||Deleporte, P.||Béhal, H.||Kerob, D.||Duhamel, A.||Mordon, Serge||Mortier, L.",,,,,,,"British Journal of Dermatology",,,"Wiley","2019","0007-0963",,,"Physique [physics]/Physique [physics]/Biophysique [physics.bio-ph]||Sciences du Vivant [q-bio]/Cancer||Sciences du Vivant [q-bio]/Ingénierie biomédicale",,,"Anglais",,,"Non",
"37c9d81c-42ef-4505-9ece-47b1a6394c56","20.500.12210/13","Compte-rendu et recension critique d'ouvrage",,,"Treating hidradenitis suppurativa with photodynamic therapy","Mordon, Serge",,,,,,,"Journal of Cosmetic and Laser Therapy",,,"Informa Healthcare","2017-12-01","1476-4172",,,"Sciences du Vivant [q-bio]||Sciences du Vivant [q-bio]/Cancer||Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Dermatologie",,"Hidradenitis suppurativa is a chronic, recurring, and disabling inflammatory condition of the skin. There is no cure for hidradenitis suppurativa and treatment must be adapted to each individual patient. Several studies have been published since 2004 on the use of photodynamic therapy to treat hidradenitis suppurativa. The use of superficial or interstitial illumination with 5-Amino-Levulinic Acid (5-ALA) or methylene blue (MB) have been proposed. Injecting 5-ALA or MB followed by illumination with a fiber optic sensor placed inside the lesion appears to be a better method of treating these thick lesions.","Anglais",,,"Non",
"3ae158b5-2bef-4d27-b7c6-c6e2e5ebc5c3","20.500.12210/13","Autre communication scientifique (congrès sans actes - poster - séminaire...)||Communication dans un congrès avec actes","10.1016/j.pdpdt.2017.01.169",,"Preliminary results on 5-ALA PDT fractionation on a preclinical rodent model","Mordon, Serge||Dupont, Clément||Betrouni, N.||Reyns, N.||Vermandel, M.||Leroy, H.A.||Quidet, M.||Leroux, B.","IPA",,"NANCY","France","2016-10-24",,,,,,"2017-03",,,,"Sciences du Vivant [q-bio]||Sciences du Vivant [q-bio]/Cancer",,"Glioblastoma Multiform (GBM) is a high-grade brain tumour with local recurrence and poor outcome. Photodynamic therapy to treat glioblastoma has been recently reported to improve overall survival. However, controlled study to evidence treatment efficacy is still expected and treatment delivery has to be optimized. Several parameters might be optimized such as fluence rate, dose escalation or fractionation of light delivery. Specially, fractionation of light delivery is expected to enhance treatment efficiency by restoring tissue oxygenation. Thus, we have evaluated light fractionation on a preclinical rodent model harbouring grafted GBM. Thirty-nine "" Nude "" rats were grafted with human U87 cells. Cells were stereotactically grafted in rat brain. After the presence and the size of the tumour were assessed by microMRI, PDT was delivered interstitially. Light was delivered through an optical fibre introduced into the tumour after PS precursor intake (5-ALA). The rats were randomized in three groups: (1) without illumination, (2) with 2-steps light fractionation and (3) with 5-steps light fraction-ation. Brain immunohistology and microMRI images were achieved to evaluate the treatment effects. On diffusion MRI, elevated diffusion values in tumour centre among treated animals were observed, especially for the 5-steps fractionation group. Perfusion decreased around the treatment site, especially in the 5-steps fractionation group. Histology confirmed our MRI findings, with a more extensive necrosis and apopto-sis associated with a rarefiedangiogenic network in the treatment area, after 5-steps fractionation PDT. However, more surrounding oedema and neovascularization in the peripheral ring after 5-steps fractionation PDT were also noticed. Finally we observed that interstitial PDT induced more tumour necrosis and apoptosis when applying 5-steps fractionation. However , this scheme also led to significant peripheral oedema and neovascularization. Diffusion and perfusion were able to predict the histological lesions. Nevertheless, apoptosis cells death remains the preferred effect in order to decrease potential side effects. We hypothesize a lower fluence rate with the same light fractionation scheme might increase apoptosis while decreasing necrosis and oedema. Preclinical study is still on going to verify this hypothesis. http://dx.","Anglais","Oui","Internationale","Non",
"bb59019c-a0df-4fe0-8870-cc4c9b28161f","20.500.12210/13","Compte-rendu et recension critique d'ouvrage","10.1051/medsci/2018225",,"La thérapie photodynamique appliquée au traitement chirurgical des glioblastomes","Dupont, Clément||Vermandel, Maximilien||Reyns, Nicolas||Mordon, Serge",,,,,,,"Médecine/Sciences",,,"EDP Sciences","2018-12-10","0767-0974",,,"Sciences du Vivant [q-bio]/Cancer||Sciences du Vivant [q-bio]","Les gliomes sont des tumeurs cérébrales primitives classés du grade I au grade IV en fonction du degré de leur malignité [1], et selon la dernière classification de l'Organisation mondiale de la santé (OMS). Parmi les gliomes de haut grade, le glioblastome (GBM) est la tumeur cérébrale primitive maligne la plus fréquente chez l'adulte avec une incidence moyenne de 4 cas par an pour 100 000 habitants en France, et une médiane de survie de 15 mois avec le traitement standard [2]. Le GBM se caractérise par la capacité d'infiltration des cellules tumorales dans le parenchyme cérébral et par sa grande hétérogénéité [3] (Voir la Nouvelle de Verreault M et al., m/s n°10, octobre 2012, page 813). Aucun facteur étiologique externe n'a, pour le moment, été rapporté, à l'exception d'une exposition à des rayonnements ionisants utilisés dans le cadre de précédentes thérapies cérébrales. Le standard de soin Un standard de soin est actuellement proposé à l'ensemble des patients nouvellement diagnostiqués [4]. Il se compose d'une résection chirurgicale lorsqu'elle est possible, suivie d'un traitement par une radio-chimiothérapie concomitante suivie d'une chimiothérapie adjuvante. La qualité de l'exérèse demeure un facteur pronostic important, qu'il s'agisse de la survie sans progression ou de la survie globale. Cette dernière est plus importante pour des patients ayant bénéficié d'une résection complète (16,9 mois de médiane) que pour ceux dont la résection a été incomplète (11,8 mois, p < 0,0001) [5].",,"Français",,,"Non",
"d48bef00-0fae-42a8-9ae7-3c4a0af26327","20.500.12210/13","Autre communication scientifique (congrès sans actes - poster - séminaire...)||Communication dans un congrès avec actes",,,"Devices based on Light Emitting Fabrics dedicated to PDTpreclinical studies","Thecua, E||Ziane, L||Baert, G||Deleporte, P.||Leroux, B.||Kumar, A.||Baydoun, M||Morales, O||Delhem, N||Mordon, Serge","""The Feminine"" 51st IPA Congress",,"Londres","Royaume-Uni","2019-07-24",,,,,,,,,"Light emitting fabrics||textile||optical||fibers||bending||PDT||preclinical studies||illumination||MDB TEXINOV","Sciences du Vivant [q-bio]||Sciences du Vivant [q-bio]/Cancer||Sciences du Vivant [q-bio]/Ingénierie biomédicale",,"Whether preclinical studies either involve a cell or animalmodel, the distribution of light plays a determinant role in the reproducibility of results of photodynamic therapy (PDT) studies. Unfortunately, only few illumination devices dedicated to preclinical studies are available and are for the most, very expensive. Mostresearch teams use home-made solutions that may not always be reproducible because of undefined light distribution, additive thermal emission, or unsuitable for shapes and volumes to illuminate. To address these issues, we developed illumination devices dedicated to our preclinical studies, which embed knitted light emitting fabrics (LEF) technology. LEF technology offers a homogeneous light distribution, without thermal emission and can be coupled with various light sources allowinginvestigation of several PDT modalities (irradiance, wavelength, illumination duration/mode). For in-vitro studies, we designed light plates,each allowing illumination of up to four 96-cells plates. For in-vivo studies, we designed mice boxes allowing three animals placement in prone position, equally surrounded by LEF and ensuring homogeneous extracorporeal illumination. Optical validation was performed and reproducibility of both preclinical systems were assessed. Both systems can deliver homogeneous light with an irradiance that can reachseveral mW/cm 2 , with varying durations and wavelengths. First results of preclinical studies demonstrate a high reproducibility, with an easy setup, and a great adaptability of illumination modalities with these devices based on light emitting fabrics.","Anglais","Oui","Internationale","Non",
"00751546-d75f-4373-91e3-79c5a5e9f746","20.500.12210/13","Compte-rendu et recension critique d'ouvrage",,,"Fluorescence guided resection and glioblastoma in 2015: A review.","Leroy, Henri-Arthur||Vermandel, Maximilien||Lejeune, Jean-Paul||Mordon, Serge||Reyns, Nicolas",,,,,,,"Lasers in Surgery and Medicine",,"441-51","Wiley","2015-05-06","0196-8092",,,"Sciences du Vivant [q-bio]/Cancer",,"AbstractHigh-grade gliomas represent a widely heterogeneous group of tumors, the most frequent of which is glioblastoma multiforme. Its annual incidence has risen over the last decades, particularly amongst elderly people. The actual standards of care allow for a 15-month median survival rate for WHO grade IV gliomas. As recurrence occurs in more than 85% of patients at the surgical margins, the initial resection extent is a cornerstone of disease control. Fluorescence guided resection (FGR) aims at increasing complete resections and, thus, local control. This technique uses 5-aminolevulinic acid (5-ALA), a natural intermediate substance in the heme-porphyrin biosynthesis pathway, and a protoporphyrin IX (PpIX) precursor. PpIX is fluorescent under blue light exposure. Recent studies reported a significant increase in complete resections using FGR, which were associated with prolonged progression free survival, fewer reinterventions, and delayed neurological deterioration. Here, we depict the principles of this surgical technique, its actual outcomes, and future developments.","Anglais",,,"Non",
"d707893b-fcf8-4ff8-8283-7c0c73a46cef","20.500.12210/13","Compte-rendu et recension critique d'ouvrage","10.3390/jcm9010192",,"An efficient Photodynamic Therapy treatment for Human Pancreatic Adenocarcinoma","Quilbe, Alexandre||Moralès, Olivier||Baydoun, Martha||Kumar, Abhishek||Mustapha, Rami||Murakami, Takashi||Leroux, Bertrand||De Schutter, Clémentine||Thecua, Elise||Ziane, Laurine||Colombeau, Ludovic||Frochot, Céline||Mordon, Serge||Delhem, Nadira",,,,,,,"Journal of clinical medicine","9||1","192","MDPI","2020","2077-0383",,,"Sciences du Vivant [q-bio]/Cancer||Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Hépatologie et Gastroentérologie||Sciences du Vivant [q-bio]/Ingénierie biomédicale",,"To date, pancreatic adenocarcinoma (ADKP) is a devastating disease for which the incidence rate is close to the mortality rate. The survival rate has evolved only 2–5% in 45 years, highlighting the failure of current therapies. Otherwise, the use of photodynamic therapy (PDT), based on the use of an adapted photosensitizer (PS) has already proved its worth and has prompted a growing interest in the field of oncology. We have developed a new photosensitizer (PS-FOL/PS2), protected by a recently published patent (WO2019 016397-A1, 24 January 2019). This photosensitizer is associated with an addressing molecule (folic acid) targeting the folate receptor 1 (FOLR1) with a high affinity. Folate binds to FOLR1, in a specific way, expressed in 100% of ADKP or over-expressed in 30% of cases. The first objective of this study is to evaluate the effectiveness of this PS2-PDT in four ADKP cell lines: Capan-1, Capan-2, MiapaCa-2, and Panc-1. For this purpose, we first evaluated the gene and protein expression of FOLR1 on four ADKP cell lines. Subsequently, we evaluated PS2’s efficacy in our cell lines and we assessed the impact of PDT on the secretome of cancer cells and its impact on the immune system. Finally, we evaluate the PDT efficacy on a humanized SCID mouse model of pancreatic cancer. In a very interesting way, we observed a significant increase in the proliferation of activated-human PBMC when cultured with conditioned media of ADKP cancer cells subjected to PDT. Furthermore, to evaluate in vivo the impact of this new PS, we analyzed the tumor growth in a humanized SCID mice model of pancreatic cancer. Four conditions were tested: Untreated, mice (nontreated), mice with PS (PS2), mice subjected to illumination (Light only), and mice subjected to illumination in the presence of PS (PDT). We noticed that the mice subjected to PDT presented a strong decrease in the growth of the tumor over time after illumination. Our investigations have not only suggested that PS2-PDT is an effective therapy in the treatment of PDAC but also that it activates the immune system and could be considered as a real adjuvant for anti-cancer vaccination. Thus, this new study provides new treatment options for patients in a therapeutic impasse and will provide a new arsenal in the fight against PDAC.","Anglais",,,"Non",
"ab5dd5a3-4c09-439f-9df3-645c0f14fca9","20.500.12210/13","Compte-rendu et recension critique d'ouvrage",,,"Evaluating the Noninferiority of a new Photodynamic Therapy (FLEXITHERALIGHT) compared with Conventional treatment for Actinic keratosis : Protocol for a Phase 2 Study","Lecomte Msc, F||Vignion-Dewalle, A||Vicentini, C.||Thecua, E||Deleporte, P||Duhamel, A||Mordon, Serge||Mortier, L",,,,,,,"JMIR research protocols",,,"JMIR publications","2019-04-26",,,,"Sciences du Vivant [q-bio]||Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Dermatologie||Sciences du Vivant [q-bio]/Cancer",,,"Anglais",,,"Non",
"c915f8f0-41de-418a-b243-166f83d4e535","20.500.12210/13","Compte-rendu et recension critique d'ouvrage","10.1097/IGC.0000000000000497",,"Fischer 344 Rat: A Preclinical Model for Epithelial Ovarian Cancer Folate-Targeted Therapy","Azais, Henri||Queniat, Gurvan||Bonner, Caroline||Kerdraon, Olivier||Tardivel, Meryem||Leroux, Bertrand||Frochot, Céline||Betrouni, Nacim||Collinet, Pierre||Mordon, Serge",,,,,,,"International Journal of Gynecological Cancer",,"1/7","Lippincott, Williams & Wilkins","2015-08-04","1048-891X",,,"Sciences du Vivant [q-bio]/Cancer",,"Objective: Ovarian cancer prognosis remains dire after primary therapy. Recurrence rates are disappointingly high as 60% of women with advanced epithelial ovarian cancer considered in remission will develop recurrent disease within 5 years. Special attention to undetected peritoneal metastasis and residual tumorous cells during surgery is necessary as they are the main predictive factors of recurrences. Folate receptor [alpha] (FR[alpha]) shows promising prospects in targeting ovarian cancerous cells. Our aim was to determine if the Fischer model described by Rose et al could be used to evaluate folate-targeted therapies in preclinical studies.Methods: NuTu-19 epithelial ovarian cancer cell line was used to induce peritoneal carcinomatosis in female Fischer 344 rats. FR[alpha] expression by NuTu-19 cells was assessed in vitro by immunofluorescence using ""Cytospin(R)"" protocol. In vitro folate-targeted compound uptake by NuTu-19 cells was evaluated by incubation of FR[alpha]-positive ovarian cancer cell lines (NuTu-19/SKOV-3/OVCAR-3/IGROV-1) with or without (control) a folate-targeted photosensitizer. Intracellular incorporation was assessed by confocal microscopy. Determination of in vivo FR[alpha] tissue expression by several organs of the peritoneal cavity was studied by immunohistochemistry.Results: NuTu-19 cells express FR[alpha] which allows intracellular incorporation of folate-targeted compound by endocytosis. FR[alpha] is expressed in tumor tissue, ovary, and liver. Peritoneum, colon, small intestine, and kidney do not express the receptor.Conclusions: Female Fischer 344 rat is an inexpensive reproducible and efficient preclinical model to study ovarian peritoneal carcinomatosis folate-targeted therapies.","Anglais",,,"Non",
"4277016b-b040-4004-ae03-046facbf3deb","20.500.12210/13","Compte-rendu et recension critique d'ouvrage",,,"Thérapie photodynamique artificielle à la lumière blanche pour la kératose actinique : une étude sur 38 patients en cabinet privé (Lettre au rédacteur en chef)","Maire, C||Vignion-Dewalle, Anne-Sophie||Cartier, H||Mordon, Serge",,,,,,,"Journal of the European Academy of Dermatology and Venereology",,,"Wiley","2019-11-07","0926-9959",,,"Sciences du Vivant [q-bio]/Cancer||Sciences du Vivant [q-bio]/Biochimie, Biologie Moléculaire/Biophysique||Sciences du Vivant [q-bio]/Ingénierie biomédicale",,,"Anglais",,,"Non",
"793e7254-d446-4033-9f2a-3cf921b7681a","20.500.12210/13","Compte-rendu et recension critique d'ouvrage","10.2196/12990","31025953","A New Light-Emitting, Fabric-Based Device for Photodynamic Therapy of Actinic Keratosis: Protocol for a Randomized, Controlled, Multicenter, Intra-Individual, Phase II Noninferiority Study (The Phosistos Study)","Vignion-Dewalle, Anne-Sophie||Abi Rached, Henry||Thecua, Elise||Lecomte, Fabienne||Deleporte, Pascal||Béhal, Hélène||Hommel, Theresa||Duhamel, Alain||Szeimies, Rolf-Markus||Mortier, Laurent||Mordon, Serge",,,,,,,"JMIR research protocols","8||4","e12990","JMIR publications","2019-04-26",,,"photodynamic therapy||light-emitting fabric||actinic keratosis||ktilite CL 128 lamp","Sciences du Vivant [q-bio]/Cancer||Sciences du Vivant [q-bio]/Ingénierie biomédicale||Sciences du Vivant [q-bio]",,"Background: Actinic keratosis (AK) is a common early in situ skin carcinoma caused by long-term sun exposure and usually develops on sun-exposed skin areas. Left untreated, AK may progress to squamous cell carcinoma. To prevent such risk, most clinicians routinely treat AK. Therapy options for AK include cryotherapy, topical treatments, curettage, excision surgery, and photodynamic therapy (PDT).Objective: The aim of this study is to assess the noninferiority, in terms of efficacy at 3 months, of a PDT protocol involving a new light-emitting device (PDT using the Phosistos protocol [P-PDT]) compared with the conventional protocol (PDT using the conventional protocol [C-PDT]) in the treatment of AK.Methods: In this randomized, controlled, multicenter, intra-individual, phase II noninferiority clinical study, subjects with AK of the forehead and scalp are treated with P-PDT on one area and with C-PDT on the contralateral area. In both areas, lesions are prepared and methyl aminolevulinate (MAL) is applied. Thirty minutes after MAL application, the P-PDT area is exposed to red light at low irradiance (1.3 mW/cm2) for 2.5 hours so that a light dose of 12 J/cm2 is achieved. In the control area (C-PDT area), a 37 J/cm2 red light irradiation is performed 3 hours after MAL application. Recurrent AK at 3 months is retreated. The primary end point is the lesion complete response rate at 3 months. Secondary end points include pain scores at 1 day, local tolerance at 7 days, lesion complete response rate at 6 months, cosmetic outcome at 3 and 6 months, and patient-reported quality of life and satisfaction throughout the study. A total of 45 patients needs to be recruited.Results: Clinical investigations are complete: 46 patients were treated with P-PDT on one area (n=285 AK) and with C-PDT on the contralateral area (n=285 AK). Data analysis is ongoing, and statistical results will be available in the first half of 2019.Conclusions: In case of noninferiority in efficacy and superiority in tolerability of P-PDT compared with C-PDT, P-PDT could become the treatment of choice for AK.Trial registration: ClinicalTrials.gov NCT03076892; https://clinicaltrials.gov/ct2/show/NCT03076892 (Archived by WebCite at http://www.webcitation.org/779qqVKek).International registered report identifier (irrid): DERR1-10.2196/12990.","Anglais",,,"Non",
"8536cdbf-8fa3-4e73-8c1c-0b1e14821d3c","20.500.12210/13","Partie d'ouvrage",,,"Targeted approaches and innovative illumination solutions:A new era for photodynamic therapy applications in gynecologic oncology?","Azais, Henri||Betrouni, Nacim||Mordon, Serge||Collinet, Pierre",,,,,,,,,,,"2015-07-14",,,,"Sciences du Vivant [q-bio]/Cancer",,"Different studies have been carried out to investigatethe potential application of photodiagnosisand photodynamic therapy (PDT) in the field of gynecological cancer treatment without finding a place in current standard clinical practice.","Anglais",,,"Non",
"1cceb9b0-9af0-43f6-ba64-b69830b2e6df","20.500.12210/13","Compte-rendu et recension critique d'ouvrage","10.1086/528990",,"Colonization of Mice by Candida albicans Is Promoted by Chemically Induced Colitis and Augments Inflammatory Responses through Galectin‐3","Jawhara, Samir||Thuru, Xavier||Standaert‐vitse, Annie||Jouault, Thierry||Mordon, Serge||Sendid, Boualem||Desreumaux, Pierre||Poulain, Daniel",,,,,,,"Journal of Infectious Diseases","197||7","972-980","Oxford University Press (OUP)","2008-04","0022-1899",,,"Sciences du Vivant [q-bio]/Biologie cellulaire",,,"Anglais",,,"Non",
"79eabcce-8f7d-4919-86c8-c6a953322ffb","20.500.12210/13","Compte-rendu et recension critique d'ouvrage","10.1002/lsm.22739","28906571","Photodynamic therapy for glioblastoma: A preliminary approach for practical application of light propagation models","Dupont, Clément||Vignion-Dewalle, Anne-Sophie||Mordon, Serge||Reyns, Nicolas||Vermandel, Maximilien",,,,,,,"Lasers in Surgery and Medicine",,"Epub ahead of print","Wiley","2017","0196-8092",,"Photodynamic Therapy||High-Grade Glioma||dosimetry||simulation||TPS","Sciences du Vivant [q-bio]/Ingénierie biomédicale||Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Chirurgie||Sciences du Vivant [q-bio]/Cancer",,"Purpose Photodynamic therapy (PDT) is a promising treatment modality to be added in the management of glioblastoma multiforme (GBM). Light distribution modeling is required for planning and optimizing PDT. Several models have been developed to predict the light propagation inside biological tissues. In the present study, two analytical methods of light propagation emitted from a cylindrical fiber source were evaluated: a discrete and a continuous method. Methods The two analytical approaches were compared according to their fluence rate results. Several cylindrical diffuse lengths were evaluated, and the relative deviation in the fluence rates was estimated. Moreover, a sensitivity analysis was conducted to compute the variance of each analytical model. Results The discrete method provided fluence rate estimations closer to the Monte-Carlo simulations than the continuous method. The sensitivity study results did not reveal significant differences between the variance of the two analytical models. Conclusions Although the discrete model provides relevant light distribution, the heterogeneity of GBM tissues was not considered. With the improvement in parallel computing that drastically decreased the computing time, replacing the analytical model by a Monte-Carlo GPU-accelerated code appeared relevant to the GBM case. Nonetheless, the analytical modeling may still function in the optimization algorithms, which might be used in the Photodynamic treatment planning system.","Anglais",,,"Non",
"659dce68-adec-4ae3-b555-45653412e1d4","20.500.12210/13","Compte-rendu et recension critique d'ouvrage","10.1016/j.pdpdt.2019.04.020",,"Parallelized Monte-Carlo using graphics processing units to model cylindrical diffusers used in photodynamic therapy: From implementation to validation","Dupont, Clément||Baert, Grégory||Mordon, Serge||Vermandel, Maximilien",,,,,,,"Photodiagnosis and Photodynamic Therapy",,,"Elsevier","2019-04-26","1572-1000",,"Monte-Carlo modeling||graphics processing unit algorithm||dosimetry||photodynamic therapy||cylindrical diffuser","Sciences du Vivant [q-bio]||Sciences du Vivant [q-bio]/Cancer||Sciences du Vivant [q-bio]/Ingénierie biomédicale",,"The Monte-Carlo method is the standard method for computing the dosimetry of both ionizing and non-ionizing radiation. Because this technique is highly time-consuming in conventional implementations, several improvements have recently been developed to speed-up simulations. Among the improvements, the use of graphics processing units (GPU) to parallelize algorithms provides a cost-efficient solution to accelerate the Monte-Carlo method. Parallel implementation of Monte-Carlo using GPU technology is described in the context of photodynamic therapy (PDT) dosimetry. This algorithm has been optimized to compute light emitted from optical fibers with cylindrical diffusers that are used in interstitial PDT applications. A comparison of the experimental measurements used to assess the results of the Monte-Carlo method is detailed. Illumination profiles of several commercially available diffusers are measured using an optical phantom that mimics the optical properties of the brain. Additionally, this Monte-Carlo method is compared to ex-vivo measurements made by a device dedicated to intraoperative PDT treatment of brain tumors. The results of the GPU Monte-Carlo validation are in accordance with the recommendations of the American Association of Physicists in Medicine. The acceleration obtained with the GPU implementation is in accordance with the literature and is sufficiently fast to be integrated in a treatment planning system dedicated to planning routine clinical interstitial PDT treatments.","Anglais",,,"Non",
"a98bcf96-b122-4e83-ac9d-a9062a5e7a14","20.500.12210/13","Communication dans un congrès avec actes","10.1016/j.pdpdt.2017.01.114",,"Latest technologies of homogeneous light distribution for photodynamic therapy of non-planar anatomical surfaces","Thecua, E.||Tylcz, J.-B.||Betrouni, N.||Mordon, Serge","IPA",,"NANCY","France","2016-10-24",,"Photodiagnosis and Photodynamic Therapy",,,,"2017-03",,,,"Sciences du Vivant [q-bio]||Sciences du Vivant [q-bio]/Cancer",,"Photodynamic therapy remains a promising treatment of precancerous and cancerous lesions in several medical fields (dermatology , gynaecology, oncology and so on.. .). To deliver an optimized light dose and prevent over – or – under treatment, a controlled, homogeneous and stable light delivery is one of the major concerns. Currently, most of sources used for photodynamic therapy do not fit with the complexity of human anatomy, and cannot ensure the homogeneity of the light delivery [1]. To overcome this issue, the development of flexible light sources could be an interesting solution. In addition to ensure a compliant therapy, the development of these technologies could provide therapeutic solutions for non-planar anatomical surfaces, such as pleural cavity, curved surfaces, and corporal extremities [2]. This communication aims to describe the different methods of optical fibres integration into a flexible structure, in order to improve light illumination during PDT. Initially, optical fibres were developed to transmit the input light energy with minimum losses to their distal end. Usually called Dis-tal End Emitting Optical Fibres (DEEOF), they use, under several conditions, the total reflection of the light property which confines light rays inside the core and propagates them along the fibre [3]. Based on the DEEOF properties, several methods were developed to enable the light emission not only distal, but through the side-surface of optical fibres. The side emission effect is the result of the light leaking from the core to the external surface of the fibre. The integration of these Side Emitting Optical Fibres (SEOF) into a flexible structures seems to be one of the best technical options to overcome the lack of homogeneity of the light distribution in PDT. Several techniques will be presented among the winding of a SEOF around a flexible material, the embroidery within a thin textile substrate, the integration of SEOF within woven and knitted structures [4].","Anglais","Oui","Internationale","Non",
"1da0feed-077d-44cf-a782-7caaa07a59c1","20.500.12210/13","Communication dans un congrès avec actes","10.1117/12.2528007",,"The role of medical imaging in the context of photodynamic therapy","Dupont, C.||Vermandel, M.||Mordon, Serge","17th International Photodynamic Association World Congress, 2019,",,"Cambridge, Massachusetts","Etats-Unis d'Amérique","2019-06-28",,"Proceedings of SPIE",,,,,,,"photodynamic therapy||medical imaging||treatment planning system||monitoring","Sciences du Vivant [q-bio]||Sciences du Vivant [q-bio]/Cancer||Sciences du Vivant [q-bio]/Ingénierie biomédicale",,"Photodynamic therapy (PDT) is a modality with promising results for the treatment of various cancers. PDT is increasingly included in the standard of care for different pathologies. The role of medical imaging in this context is crucial to better understand how and where to deliver the therapy but also to observe the different mechanisms involved in the effects on tumors. At different stages of delivery, PDT requires imaging to plan, evaluate and monitor treatment. In this paper, we review the contribution of Magnetic Resonance Imaging or Positron Emission Tomography for planning and therapeutic monitoring purposes. Several solutions have been proposed to plan PDT from imaging. MRI and dedicated segmentation algorithm have been recently proposed to plan interstitial PDT with stereotactic localization and light diffusion simulation capabilities. Additionally, photosensitizer biodistribution has been evaluated with radiolabeled photosensitizers. The effects of PDT delivery have also been explored with specific Magnetic Resonance Imaging or Positron Emission Tomography radiopharmaceuticals to evaluate the effects on cells (apoptosis, necrosis, proliferation, metabolism) or vascular damage. The contribution of medical imaging in the context of photodynamic therapies is important and continues to increase. Using morphological or molecular imaging has to be considered for future developments of PDT.","Anglais","Oui","Internationale","Non",
"60fbd997-5b7d-4ec3-b0a6-97942a901861","20.500.12210/13","Compte-rendu et recension critique d'ouvrage",,,"Photodiagnostic et chirurgie guidés par la fluorescence","Mordon, Serge||Bourg-Heckly, Geneviève",,,,,,,"L'Actualité Chimique",,"1-15","Société chimique de France (SCF)","2015-06-30","0151-9093","Fluorescence||laser||light||cancer||surgery||diagnosis  Les marqueurs fluorescents",,"Sciences du Vivant [q-bio]/Cancer","Pour de nombreux cancers, plus le diagnostic est réalisé précocement, moins les traitements sont lourds et meilleures sont les chances de guérison. L'utilisation de méthodes optiques de diagnostic précoce, basées sur des mesures de fluorescence (photodiagnostic) repose soit sur une fluorescence naturelle, soit sur la répartition d'un marqueur fluorescent permettant de distinguer le tissu tumoral du tissu sain. En cancérologie, l'ablation chirurgicale complète de la tumeur est un des facteurs pronostiques des plus importants pour la survie du patient. Grâce à un marquage spécifique des tumeurs, il est maintenant possible de procéder à l'exérèse macroscopique la plus complète possible de la tumeur en limitant les atteintes lésionnelles sur les tissus sains. On parle alors de chirurgie guidée par la fluorescence. Mots-clés Fluorescence, laser, cancer, chirurgie, diagnostic. Abstract Fluorescence diagnosis and fluorescence-guided surgery For many cancers, earlier diagnosis makes treatments less heavy and increases the chances of recovery. Fluorescence diagnosis has become an important method of investigation in clinical practice. It is used to distinguish tumor tissue from healthy tissue, thanks to differences in autofluorescence of specific proteins or in distribution of a fluorescent marker between normal and cancerous lesions. Similarly, complete surgical removal of the tumor is one of the most important prognostic factors for survival of the patient. Fluorescence-guided surgery is now proposed to perform the most complete macroscopic resection of tumors while preserving healthy tissue.",,"Français",,,"Non",
"d6784c18-4b9d-4ba8-8281-a9212cd8e5be","20.500.12210/13","Compte-rendu et recension critique d'ouvrage",,,"Photodynamic therapy for atherosclerosis. The potential of Indocyanine Green","Houthoofd, Sabrina||Vuylsteke, M||Mordon, Serge||Fourneau, I",,,,,,,"Photodiagnosis and Photodynamic Therapy",,,"Elsevier","2019-10-04","1572-1000",,,"Sciences du Vivant [q-bio]/Biochimie, Biologie Moléculaire/Biophysique||Sciences du Vivant [q-bio]/Ingénierie biomédicale",,"Aim: The aim of this article is to summarize and review the use of photodynamic therapy for the treatment of atherosclerotic plaque and the prevention of intimal hyperplasia. Different photosensitizers are discussed and more specific the role of indocyanine green as a potential photosensitizer. Methods: Literature search with focus on the use of photodynamic therapy in atherosclerosis, the mechanism of action and the different photosensitizers for photodynamic therapy. Results: In-vitro and in-vivo studies confirm the use of photodynamic therapy for the treatment of atherosclerosis and the prevention of restenosis. Non-specific accumulation of photosensitizer and thus phototoxicity, remains an important problem. Indocyanine green is a photosensitizer","Anglais",,,"Non",
"4054eba0-54c8-49ad-b163-59113a8086f7","20.500.12210/13","Compte-rendu et recension critique d'ouvrage","10.1016/j.ccr.2022.214702",,"Folate-based radiotracers for nuclear imaging and radionuclide therapy","Wagner, Laurène||Kenzhebayeva, Bibigul||Dhaini, Batoul||Boukhlef, Samir||Moussaron, Albert||Mordon, Serge||Frochot, Céline||Collet, Charlotte||Acherar, Samir",,,,,,,"Coordination Chemistry Reviews","470","214702","Elsevier","2022-11-01","0010-8545",,"Folic acid||Ovarian cancer||Radiopharmaceutical||Nuclear imaging||Targeted radionuclide therapy||Theranostic","Chimie/Radiochimie",,"Folate receptor α (FRα) is overexpressed on numerous tumorous cell types such as ovarian or endometrial cancer cells. Moreover, FRα is absent from most healthy tissues as it is normally expressed only on the surface of proximal tubules cells of kidneys and choroid plexus. Thus, folate-based radiopharmaceuticals have emerged this last two decades as FRα is a target of choice to diagnose and treat numerous cancers. Nuclear imaging is a performing diagnostic technology using highly sensitive detectors and specific radiopharmaceuticals used to detect tumors at an earlier stage. Herein, an overview of the development of folate-based radiopharmaceuticals to detect FRα-positive tumors by nuclear imaging using positron emission tomography (PET) and single photon emission computed tomography (SPECT) is exposed. Strategies developed to improve precursor synthesis, bioavailability, clearance, and affinity to FRα will be detailed. Advances made to decrease kidney uptake open the gate to targeted radionuclide therapy (TRT) using folate-based radiopharmaceuticals to treat FRα-positive tumors. Thus, radiofolates used in TRT and more precisely in a theranostic approach will be depicted in this review","Anglais",,,"Non",
"38fe5493-c592-4256-aa9d-d8412ac5fa25","20.500.12210/13","Communication dans un congrès avec actes","10.1117/12.2526248",,"Feasibility trial assessing intrapleural photodynamic therapy combined with pleurectomy/decortication then chemotherapy in malignant pleural mesothelioma patients","Mordon, Serge||Munck, Camille||Surmei-Pintilie, Ecaterina||Akkad, Rias||Wasielewski, Eric||Baert, Grégory||Deleporte, Pascal||Porte, Henri||Scherpereel, Arnaud","17th International Photodynamic Association World Congress",,"Cambridge, Massachusetts","Etats-Unis d'Amérique","2019-06-28",,"Proceedings of SPIE",,,,,,,,"Sciences du Vivant [q-bio]||Sciences du Vivant [q-bio]/Cancer||Sciences du Vivant [q-bio]/Ingénierie biomédicale",,,"Anglais","Oui","Internationale","Non",
"84ce124f-0281-4e83-9e55-6e735c0653b5","20.500.12210/13","Compte-rendu et recension critique d'ouvrage","10.3390/ph14020138",,"Photophysical Properties of Protoporphyrin IX, Pyropheophorbide-a and Photofrin® in Different Conditions","Myrzakhmetov, Bauyrzhan||Arnoux, Philippe||Mordon, Serge||Acherar, Samir||Tsoy, Irina||Frochot, Céline",,,,,,,"Pharmaceuticals","14||2","138","MDPI","2021-02-09","1424-8247",,"Photofrin®||Absorption||Fluorescence||Photodynamic therapy||Protoporphyrin IX||pyropheophorbide-a||Singlet oxygen","Chimie/Chimie thérapeutique",,"Photodynamic therapy (PDT) is an innovative treatment of malignant or diseased tissues. The effectiveness of PDT depends on light dosimetry, oxygen availability, and properties of the photosensitizer (PS). Depending on the medium, photophysical properties of the PS can change leading to increase or decrease in fluorescence emission and formation of reactive oxygen species (ROS) especially singlet oxygen (1O2). In this study, the influence of solvent polarity, viscosity, concentration, temperature, and pH medium on the photophysical properties of protoporphyrin IX, pyropheophorbide-a, and Photofrin® were investigated by UV-visible absorption, fluorescence emission, singlet oxygen emission, and time-resolved fluorescence spectroscopies.","Anglais",,,"Non",
"a89ac26b-4e0c-4df1-8294-2ca29c6c2be1","20.500.12210/13","Compte-rendu et recension critique d'ouvrage","10.1002/lsm.22827",,"Comparison of 10 efficient protocols for photodynamic therapy of actinic keratosis: How relevant are effective light dose and local damage in predicting the complete response rate at 3 months?","Vignion-Dewalle, Anne-Sophie||Baert, Grégory||Thecua, Elise||Lecomte, Fabienne||Vicentini, Claire||Abi-Rached, Henry||Mortier, Laurent||Mordon, Serge",,,,,,,"Lasers in Surgery and Medicine",,,"Wiley","2018-04-18","0196-8092",,,"Sciences du Vivant [q-bio]||Sciences du Vivant [q-bio]/Cancer",,,"Anglais",,,"Non",
"ddb6df8e-49de-4801-96e7-5de0d6595223","20.500.12210/13","Compte-rendu et recension critique d'ouvrage",,,"Interstitial 5-ALA photodynamic therapy and glioblastoma: preclinical model development and preliminary results.","Tetard, Marie-Charlotte||Vermandel, Maximilien||Leroy, Henri-Arthur||Leroux, Bertrand||Maurage, Claude-Alain||Lejeune, Jean-Paul||Mordon, Serge||Reyns, Nicolas",,,,,,,"Elsevier",,"1/7",,"2015",,,,"Sciences du Vivant [q-bio]/Cancer",,"AbstractOBJECTIVE: Photodynamic therapy (PDT) has become a well-established modality for the treatment of many cancers. Photodynamic eradication of tumor cells depends on the presence of a photosensitizer, oxygen and light. However, oxygen depletion during PDT is a well known problem. Modulation of light delivery could address this issue by counteracting tumor hypoxia, thereby improving tumor cell killing. This preclinical study was designed to validate an animal model incorporating 5-aminolaevulinic acid (5-ALA)-PDT using U87 glioblastoma cells. We aimed to evaluate the effects of light modulation for inducing specific tumoral lesions in this model (i.e., necrosis or apoptosis).MATERIALS AND METHODS: U87 glioblastoma cells were stereotactically engrafted into the brains of male fox1 rnu/rnu rats. Light delivery was studied after 5-ALA injection (100mg/kg i.p.). 26J of 635nm light was interstitially delivered to U87 tumor-bearing rats at a radiant power of either 30 mW (high fluence rate) or 4.8 mW (low fluence rate). In each group, half of the population received illumination in 2 fractions with a refractory interval of 120seconds, whereas the other half received continuous illumination.RESULTS: Twenty-two animals received 5-ALA-PDT, and the level of necrosis was scored. In the high-fluence-rate group, we observed a greater degree of tumor necrosis in rats receiving fractionated delivery than in rats receiving continuous illumination. Similar differences were not observed in the low-fluence-rate group, which exhibited only sparse necrosis. Higher morbidity and mortality rates were observed in the high-fluence-rate group.CONCLUSION: We have developed a reproducible and reliable rodent model for interstitial 5-ALA PDT. We found that the effects of 5-ALA-PDT are dependent on light delivery conditions. Although the low-fluence-rate treatment was better tolerated, 5-ALA-PDT induced more necrosis using fractionated delivery at a high fluence rate. These results require confirmation with further studies involving larger populations and additional fractionation schemes.","Anglais",,,"Non",
"3566420b-816f-407e-a182-a982840e3e8d","20.500.12210/13","Compte-rendu et recension critique d'ouvrage",,,"New optical sources for interstitial and metronomic photodynamic therapy","Mordon, Serge",,,,,,,"Photodiagnosis and Photodynamic Therapy",,,"Elsevier","2018-09-07","1572-1000",,,"Sciences du Vivant [q-bio]/Cancer||Sciences du Vivant [q-bio]||Sciences du Vivant [q-bio]/Ingénierie biomédicale",,,"Anglais",,,"Non",
"a2e958c1-9980-41df-8b1f-796ce3c541e3","20.500.12210/13","Compte-rendu et recension critique d'ouvrage","10.1051/medsci/2019008",,"Trois chercheurs, dont un Français, récompensés pour leurs travaux sur les lasers","Mordon, Serge",,,,,,,"Médecine/Sciences","35||2","176-177","EDP Sciences","2019","0767-0974",,,"Sciences du Vivant [q-bio]/Ingénierie biomédicale||Physique [physics]/Physique [physics]/Optique [physics.optics]",,,"Français",,,"Non",
"c2edc3fd-f9b8-4bb7-bd97-d78f222dbe17","20.500.12210/13","Compte-rendu et recension critique d'ouvrage",,,"Can daylight-PDT be performed indoor?","Mordon, Serge||Vignion-Dewalle, A||Thecua, E||Vicentini, C||Maire, C||Deleporte, P.||Baert, G||Lecomte, F.||Mortier, L",,,,,,,"GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA",,,"Edizioni Minerva medica","2018-02-07","0392-0488",,,"Sciences du Vivant [q-bio]||Sciences du Vivant [q-bio]/Cancer",,"Natural DayLight-mediated PhotoDynamic Therapy (NDL-PDT) is an efficacious treatment option for thin actinic keratosis that offers advantages over conventional PDT in terms of tolerability, treatment duration, and cost.","Anglais",,,"Non",
"aa41e300-d341-47ee-8efc-d22d2748efd3","20.500.12210/13","Compte-rendu et recension critique d'ouvrage","10.3390/ijms21124292",,"Novel Therapies Boosting T Cell Immunity in Epstein Barr Virus-Associated Nasopharyngeal Carcinoma","Renaud, Sarah||Lefebvre, Anthony||Mordon, Serge||Morales, Olivier||Delhem, Nadira",,,,,,,"International Journal of Molecular Sciences","21||12","4292","MDPI","2020","1661-6596",,"therapy||T cell||immunity||EBV||nasopharyngeal carcinoma","Sciences du Vivant [q-bio]/Cancer||Sciences du Vivant [q-bio]/Immunologie/Immunothérapie",,"Nasopharyngeal carcinoma (NPC) is a malignant tumour of the head and neck affecting localised regions of the world, with the highest rates described in Southeast Asia, Northern Africa, and Greenland. Its high morbidity rate is linked to both late-stage diagnosis and unresponsiveness to conventional anti-cancer treatments. Multiple aetiological factors have been described including environmental factors, genetics, and viral factors (Epstein Barr Virus, EBV), making NPC treatment that much more complex. The most common forms of NPCs are those that originate from the epithelial tissue lining the nasopharynx and are often linked to EBV infection. Indeed, they represent 75-95% of NPCs in the low-risk populations and almost 100% of NPCs in high-risk populations. Although conventional surgery has been improved with nasopharyngectomy's being carried out using more sophisticated surgical equipment for better tumour resection, recent findings in the tumour microenvironment have led to novel treatment options including immunotherapies and photodynamic therapy, able to target the tumour and improve the immune system. This review provides an update on the disease's aetiology and the future of NPC treatments with a focus on therapies activating T cell immunity.","Anglais",,,"Non",
"3971a278-86c8-4810-844d-04392a185cb9","20.500.12210/13","Compte-rendu et recension critique d'ouvrage","10.3390/ijms21186772","32942768","Combination of High Dose Hypofractionated Radiotherapy with Anti- PD1 Single Dose Immunotherapy Leads to a Th1 Immune Activation Resulting in a Complete Clinical Response in a Melanoma Patient","Milhem, Clara||Moralès, Olivier||Ingelaere, Céline||Pasquier, David||Mordon, Serge||Mortier, Laurent||Mirabel, Xavier||Delhem, Nadira",,,,,,,"International Journal of Molecular Sciences","21||18","6772","MDPI","2020-09-15","1661-6596",,"stereotaxic radiotherapy||immunotherapy||anti-PD1||melanoma||immune response","Sciences du Vivant [q-bio]||Sciences du Vivant [q-bio]/Cancer||Sciences du Vivant [q-bio]/Immunologie",,"The development of immunotherapy has recently modified the anti-tumor therapeutic arsenal ; particularly, immune checkpoint inhibitors have led to a significant increase in overall survival. The current challenge is now to select good responder patients by identifying early biomarkers to propose therapeutic combinations that potentiate the efficacy of the therapy. Here we report the case of a 60-year-old man with superficial melanoma treated with high-dose hypo fractionated radiotherapy (H-SRT) combined with a single dose of anti-PD1 immunotherapy (Nivolumab) for a metastatic lymph node recurrence due to cancer progression. In this study, we present the results obtained regarding the activation of the Th1 immune response after H-SRT treatment followed by anti PD-1 therapeutic protocol. These results were correlated with clinical data to identify potential immunological biomarkers of treatment efficacy. This exceptional case report shows that a combination of H-SRT with a single dose of anti-PD1 immunotherapy may allow a better activation of the immune response in favor of a complete clinical response.","Anglais",,,"Non",
"15cd7443-8894-4e45-b290-6631cc06bb80","20.500.12210/13","Compte-rendu et recension critique d'ouvrage",,,"La communication sous forme d’un jeu de plateau pour partager des données et des ressentis d’experts à propos d’un nouveau traitement contre le cancer","Goria, Stéphane||Boninsegna, Cléo||Landon, Juliette||Frochot, Céline||Vicentini, Claire||Munck, Camille||Mordon, Serge||Anne, Valentine",,,,,,,"Recherches en communication","49","71-91","Centre de recherche en communication, Université Catholique de Louvain","2019-04-10",,"ludification||explicitation de connaissances||gestion des connaissances||jeu||jeu de plateau||thérapie photdyniamique||visualisation de données||Analyse multivariée","gamification||knowledge elicitation||data visualization||game design||board game||photodynamic therapy||knowledge management||Multivariate analysis||interdisciplinarirty||Interdiscipinarité","Sciences de l'Homme et Société/Sciences de l'information et de la communication||Sciences du Vivant [q-bio]/Cancer||Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Dermatologie","La conception de cartes à des fins de communication ou, de manière plus générale, la visualisation de données est un champ de recherches relativement ancien qui a subi de profonds changements au cours de ces dernières années. Si de nombreuses recherches y sont consacrées, très peu d’entre elles s’intéressent à une autre tendance forte du moment : l’emploi ou le détournement du jeu à des fins de communication. Ce papier traite de cette question en abordant le cas d’un support informationnel rappelant un jeu de stratégie sur plateau développé dans un but d’information à propos d’un nouveau procédé de lutte contre le cancer : la thérapie photodynamique.","The design of maps for communication purposes or, more generally, data visualization is a relatively old field of research that has undergone profound changes in recent years. While a great deal of research has been devoted to this field, very little of it has focused on another major current trend: the use or hijacking of games for communication purposes. This paper deals with this issue by examining the case of an informational medium reminiscent of a strategy board game developed to inform people about a new cancer treatment: photodynamic therapy.","Français",,,"Non",
"3f242f58-7cd3-460d-8aa2-88c14dc8f3e4","20.500.12210/13","Compte-rendu et recension critique d'ouvrage","10.1093/neuros/nyy324","30053213","Thérapie photodynamique peropératoire du glioblastome (INDYGO): protocole clinique d'étude de phase I","Dupont, Clément||Vermandel, Maximilien||Leroy, Henri-Arthur||Quidet, Mathilde||Lecomte, Fabienne||Delhem, Nadira||Mordon, Serge||Reyns, Nicolas",,,,,,,"Neurosurgery",,"Epub ahead of print","Lippincott, Williams & Wilkins","2018-07-21","0148-396X",,,"Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Chirurgie||Sciences du Vivant [q-bio]/Cancer||Sciences du Vivant [q-bio]/Ingénierie biomédicale||Sciences du Vivant [q-bio]/Immunologie",,"BACKGROUND:Glioblastoma (GBM) is characterized by marked proliferation, major infiltration, and poor prognosis. Despite current treatments, including surgery, radiation oncology, and chemotherapy, the overall median survival is 15 mo and the progression-free survival is 7 to 8 mo. Because of systematic relapse of the tumor, the improvement of local control remains an issue. In this context, photodynamic therapy (PDT) may offer a new treatment modality for GBM.OBJECTIVE:To assess the feasibility of intraoperative PDT early after surgical resection of GBM without unacceptable and unexpected toxicities.METHODS:The INDYGO clinical trial (INtraoperative photoDYnamic Therapy for GliOblastomas) treatment will be carried out in addition to the current standard of care (SOC) of glioblastoma: maximum resection surgery followed by concomitant radio-chemotherapy and adjuvant chemotherapy. PDT treatment will be delivered during surgery early, after the fluorescence-guided resection. Immunological responses and biomarkers will also be investigated during the follow-up. A total of 10 patients will be recruited during this study.EXPECTED OUTCOMES:Clinical follow-up after the SOC with PDT is expected to be similar (no significant difference) to the SOC alone.DISCUSSION:This INDYGO trial assesses the feasibility of intraoperative 5-aminolevulinic acid PDT, a novel seamless approach to treat GBM. The technology is easily embeddable within the reference treatment at a low-incremental cost. The safety of this new treatment modality is a preliminary requirement before a multicenter randomized clinical trial can be further conducted to assess local control improvement by treating infiltrating and nonresected GBM cells.","Anglais",,,"Non",
"52d077c6-b4ac-41d2-af3f-3be794f54b74","20.500.12210/13","Compte-rendu et recension critique d'ouvrage",,,"Letter to the Editor : Painless and efficient ALA-PDT and MAL-PDT of Actinic Keratosis can be achieved by drastically reducing the Drug-Light Interval (DLI)","Mordon, Serge",,,,,,,"Dermatologic Therapy",,,"Wiley","2020-04-17","1396-0296",,,"Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Dermatologie||Sciences du Vivant [q-bio]||Sciences du Vivant [q-bio]/Cancer||Sciences du Vivant [q-bio]/Ingénierie biomédicale",,,"Anglais",,,"Non",
"46fa2574-0209-40db-96c5-f96dbd9d22bb","20.500.12210/13","Compte-rendu et recension critique d'ouvrage","10.1002/lsm.22744","29023876","MRI assessment of treatment delivery for interstitial photodynamic therapy of high-grade glioma in a preclinical model","Leroy, Henri-Arthur||Vermandel, Maximilien||Leroux, Bertrand||Duhamel, Alain||Lejeune, Jean-Paul||Mordon, Serge||Reyns, Nicolas",,,,,,,"Lasers in Surgery and Medicine",,"Epub ahead of print","Wiley","2017-10-11","0196-8092",,"5-ALA||MRI||PDT||PpIX||glioblastoma||high-grade glioma||magnetic resonance imaging||photodynamic therapy","Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Chirurgie||Sciences du Vivant [q-bio]||Sciences du Vivant [q-bio]/Neurosciences [q-bio.NC]||Sciences du Vivant [q-bio]/Cancer",,"BACKGROUND:High-grade gliomas are primary brain tumors that have shown increasing incidence and unfavorable outcomes. Local control is crucial to the management of this pathology. Photodynamic therapy (PDT), based on the light-induced activation of a photosensitizer (PS), achieves local treatment by inducing selective lesions in tumor tissue.OBJECTIVES:Previous studies have reported the outcomes of PDT for glioblastoma via immunohistological data. Our study aimed to evaluate MRI findings, including diffusion, and perfusion sequences, compared with immunohistological data from the same population to address the efficiency of light fractionation.MATERIALS AND METHODS:Twenty-six ""nude"" rats grafted with human U87 cells into the right putamen underwent PDT. After PS precursor (5-ALA) intake, an optical fiber was introduced into the tumor. The rats were randomized into the following groups: those without illumination and those that received two or five fractions of light. Treatment effects were assessed with early high-field MRI to measure the volume of necrosis and edema using diffusion and perfusion sequences; the MRI results were compared with immunohistology results, including necrosis and apoptosis markers.RESULTS:Elevated diffusion values were observed on MRI in the centers of the tumors of the treated animals, especially in the 5-fraction group (P < 0.01). Perfusion was decreased around the treatment site, especially in the 5-fraction group (P = 0.024). The MRI findings were consistent with previously published histological data. The median volume of necrosis was significantly different between the sham group and treated groups, 0 mm3 versus 2.67 mm3 , P < 0.001. The same trend was previously observed in histology data when grading the absence or presence of necrosis and when the presence of necrosis was significantly more predominant for the treated group than for the untreated group (P < 001). Additionally, cell death represented by apoptosis marker data (TUNEL method) was significantly higher in the 5-fraction group than in the 2-fraction group (P = 0.01).CONCLUSION:Diffusion and perfusion MRI revealed histological lesions. Interstitial PDT (iPDT) induced specific lesions in the tumor tissue, which were observed with MRI and confirmed by histopathological analysis. Thus, MRI may provide a non-invasive and reliable tool to assess treatment outcomes after PDT. Lasers Surg. Med. © 2017 Wiley Periodicals, Inc.","Anglais",,,"Non",
"6d1aab36-0303-4dd0-9f13-86d0d825ebc1","20.500.12210/13","Autre communication scientifique (congrès sans actes - poster - séminaire...)||Communication dans un congrès avec actes",,,"DOSINDYGO -DOSe finding for INtraoperative photoDYnamic therapy of GliOblastoma","Dupont, C.||Lecomte, F.||Deleporte, P.||Baert, G||Mordon, Serge||Reyns, N.||Vermandel, M.","17th International Photodynamic Association World Congress",,"Cambridge, Massachusetts","Etats-Unis d'Amérique","2019-06-28",,,,,,,,,"photodynamic therapy||glioblastoma||clinical trial||light dose escalation","Sciences du Vivant [q-bio]||Sciences du Vivant [q-bio]/Cancer||Sciences du Vivant [q-bio]/Ingénierie biomédicale",,"Glioblastoma is a malignant brain tumor with a poor prognosis. Currently, complete resection is rarely feasible, since tumor cells usually infiltrate the surrounding brain. Recently, the INDYGO clinical trial has been achieved to assess the toxicity of photodynamic therapy (PDT) delivered intraoperatively to treat newly diagnosed glioblastoma. Today, we believe that the PDT effect obtained in the INDYGO clinical trial can be improved by a higher light dose. The DOSINDYGO clinical trial aims to achieve a light-dose escalation increasing up to four times the initial light dose used in the INDYGO trial. An increase of both light power and treatment time should allow to treat deeper in the surrounding tissues (up to 8mm) and thus decrease the recurrence risk. First light dose will be reached by doubling the treatment time used in the INDYGO trial, the other one will be achieved by increasing light power only. This methodology was chosen in order to maintain an acceptable treatment time for anesthesia but also to prevent higher fluence rate that could induce a lower tolerance as observed in our preclinical results. Primary endpoint will be to determine the optimum light-dose regarding the ratio efficacy and tolerance of the treatment. Primary criterion is the assessment of the progression free survival within the bed border's cavity. Finally, although no adverse effect has been noticed during the INDYGO trial, increasing light dose in this DOSINDYGO trial could result in other direct and indirect biological effects.","Anglais","Oui","Internationale","Non",
"63537b53-d690-4ebf-ae40-583718ce280f","20.500.12210/13","Autre communication scientifique (congrès sans actes - poster - séminaire...)||Communication dans un congrès avec actes",,,"LIGHT EMITTING FABRICS FOR PHOTODYNAMIC TREATMENT OF VULVAR PRIMARY EXTRAMAMMARY PAGET'S DISEASE","Thecua, E||Lecomte, F||Ziane, L||Vignion, A-S||Maire, C||Vicentini, C||Abirached, H||Staumont, D||Mortier, L||Mordon, Serge","""The Feminine"" 51st IPA Congress",,"Londres","Royaume-Uni","2019-07-24",,,,,,"2019-08-07",,,"Light emitting fabrics||textile||Extramammary Paget's disease||photodynamic therapy","Sciences du Vivant [q-bio]||Sciences du Vivant [q-bio]/Cancer||Sciences du Vivant [q-bio]/Ingénierie biomédicale",,"Primary Extramammary Paget's disease (EMPD) is a rare cancer that mainly affects the genital region including vulvar and perianal areas. Without treatment, vulvar EMPD progresses and presents always more erythematous and pruritic plaques, which may become ulcerated and erosive. To control disease progression and symptoms usually experienced by patients, surgical excision is the mainstay of treatment. Unfortunately, even after large surgical excision with intra-operative margin control, recurrences are common [1]. For recurrent patients which undergo multiple resections, severe functional and sexual alterations are described. Only few data are available on the efficacy of alternative conservative treatments, such as laser ablation, radiotherapy, topical chemotherapy and photodynamic therapy (PDT) [2]. To date, none of them can be considered as a solid alternative to surgical excision yet [3]. Nonetheless, multiple clinical cases suggest that PDT could provide the opportunity to treat subclinical lesions, and give some relief on patient's symptoms of the disease [4-6]. Unfortunately, the benefits of using photodynamic therapy for vulvar EMPD remains a challenge to demonstrate, because of the inhomogeneous illumination of vulvar and perianal areas, and the extreme pain that patients usually experienced during the illumination procedure that may lead to premature end of treatment [7, 8]. Resulting from the knowledge of previous works on actinic keratosis of the scalp treatment with PDT, light emitting fabrics (LEF) technology could address both of the hereinbefore described issues [9-12]. A new medical device based on LEF named PAGETEX® dedicated to illumination of vulvar and perianal areas has been developed. The device delivers a homogeneous red light (635 nm) with a low irradiance during 2h30, for a total fluence of 12 J/cm². The PAGETEX® device is being assessed in a clinical study (NCT03713203) which aims to establish PAGETEX®-PDT efficacy and tolerability.","Anglais","Oui","Internationale","Non",
"4b9040d3-9731-4568-b989-e7b1f4fb3ee4","20.500.12210/13","Compte-rendu et recension critique d'ouvrage","10.1111/dth.12913",,"Low-irradiance red light compared to conventional red light in photodynamic therapy of actinic keratosis: a way to reduce pain during treatment","Mordon, Serge||Vignion-Dewalle, Anne-Sophie",,,,,,,"Dermatologic Therapy",,,"Wiley","2019-04-09","1396-0296",,,"Sciences du Vivant [q-bio]/Cancer||Sciences du Vivant [q-bio]||Sciences du Vivant [q-bio]/Ingénierie biomédicale",,,"Anglais",,,"Non",
"991b254a-086e-4163-98e7-eea5434ace6f","20.500.12210/13","Compte-rendu et recension critique d'ouvrage",,,"Computer-aided analysis of prostate multiparametric MR images: an unsupervised fusion-based approach","Betrouni, Nacim||Makni, Nasr||Lakroum, S||Mordon, Serge||Villers, Arnaud||Puech, Pascal",,,,,,,"International Journal of Computer Assisted Radiology and Surgery",,"01/12","Springer Verlag","2015-01-22","1861-6410",,,"Sciences du Vivant [q-bio]/Cancer",,"OBJECTIVE: The aim of this study is to provide an automatic framework for computer-aided analysis of multiparametric magnetic resonance (mp-MR) images of prostate.METHOD: We introduce a novel method for the unsupervised analysis of the images. An evidential C-means classifier was adapted for use with a segmentation scheme to address multisource data and to manage conflicts and redundancy.RESULTS: Experiments were conducted using data from 15 patients. The evaluation protocol consisted in evaluating the method abilities to classify prostate tissues, showing the same behaviour on the mp-MR images, into homogeneous classes. As the actual diagnosis was available, thanks to the correlation with histopathological findings, the assessment focused on the ability to segment cancer foci. The method exhibited global sensitivity and specificity of 70 and 88 %, respectively.CONCLUSION: The preliminary results obtained by these initial experiments showed that the method can be applied in clinical routine practice to help making decision especially for practitioners with limited experience in prostate MRI analysis.","Anglais",,,"Non",
"37331ab0-8031-4f6b-a47c-1902ec6f1ef6","20.500.12210/13","Partie d'ouvrage",,,"Assessment of the specificity of a new folate-targeted photosensitizer for peritoneal metastasis of epithelial ovarian cancer to enable intraperitoneal photodynamic therapy. A preclinical study.","Azais, Henri||Schmitt, Caroline||Tardivel, Meryem||Kerdraon, Olivier||Stallivieri, Aurélie||Frochot, Céline||Betrouni, Nacim||Collinet, Pierre||Mordon, Serge",,,,,,,,,,,"2015-07-14",,,,"Sciences du Vivant [q-bio]/Cancer",,"The prognosis of advanced epithelial ovarian cancer remains poor. The current treatment  is the association of complete macroscopic cytoreductive surgery and platinum-based chemotherapy. It is accepted that the absence of residual disease after surgery is a key to improve prognosis. 60 % of patients treated by complete cytoreductive surgery and chemotherapy will develop peritoneal recurrence.","Anglais",,,"Non",
"b127dcb7-0753-4ffd-ab3e-ae3cb7ef948e","20.500.12210/13","Compte-rendu et recension critique d'ouvrage","10.1016/j.pdpdt.2017.01.075",,"Real-time light dosimetry for intra-cavity photodynamic therapy","Soltana, W||Munck, C||Baert, G||Mordon, Serge||Betrouni, N.",,,,,,,"Photodiagnosis and Photodynamic Therapy","17","A34","Elsevier","2017-03","1572-1000",,,"Sciences du Vivant [q-bio]||Sciences du Vivant [q-bio]/Cancer",,"Photodynamic therapy (PDT) is an emerging technic in oncology. The success by the achievement of the desired therapeutic effect of a PDT procedure relies on the accurate photosensitizer (PS) concentration distribution in tissues and on the homogeneous light delivery. To resolve the last issue in presence of the variability in target geometries (volume, elastic, solid, hollow organs and cavities), we propose a novel approach based on the light distribution modeling combined with spatial localization of the light applicator and real time display of the applied dose using computed tomogra-phy (CT) images. CT scans of the thorax cavity are acquired before the surgery to construct the thorax cavity. Fiducial markers consisting of 5 mm diameter capsule filled with paraffin oil are attached to the patient around the region to be imaged. A spatial registration is applied to compute a transformation between the patient position in the operating room and the images. The light distribution profile around the diffusing tip of the light applicator was characterized by two complementary methods: direct measurements of the light power using sensors and dose distribution characterization using a light sensitive camera. This model takes into account the absorption and the diffusion around the applicator. For the real time localiza-tion of the light applicator, an electromagnetic 3D tracking device is used to track the applicator movements. This tracking system is composed of a control unit with plugs to connect a transmitter and up to 4 six degrees-of-freedom sensors. By combining the model and the positions, a complete 3D light dose distribution is estimated and displayed on the CT images. The validation of the approach is realized in the conditions of a protocol of malignant pleural mesothelioma treatment. To compare and evaluate our estimated light dose, we operate direct measurements of the light power, as it was done in the work by Zhu et al. [1], using sensors that consist of isotropic probes able of collecting lights from different direction. All them are connected to a dosimetry system composed of an optical multiplexer, an optical power-meter, and a home-made software. Preliminary experiments of the method are conducted on a thorax phantom. The surface of the chest wall of the phantom was 1270 cm 2. With a laser emitting at 3 W, the treatment was performed for 10 nm. As results, differences less than 10% were observed between the measured values and the model based estimations. Reference [1] T.","Anglais",,,"Non",
"8ac35fb4-9b5b-4146-9303-53e5ea6664ab","20.500.12210/13","Compte-rendu et recension critique d'ouvrage",,,"Comparison of different treatment schemes in 5-ALA interstitial photodynamic therapy for high-grade glioma in a preclinical model: An MRI study","Vermandel, Maximilien||Quidet, Mathilde||Vignion-Dewalle, Anne-Sophie||Leroy, Henri-Arthur||Leroux, Bertrand||Mordon, Serge||Reyns, Nicolas",,,,,,,"Photodiagnosis and Photodynamic Therapy",,,"Elsevier","2018-12-10","1572-1000",,,"Sciences du Vivant [q-bio]/Cancer||Sciences du Vivant [q-bio]/Ingénierie biomédicale||Physique [physics]/Physique [physics]/Biophysique [physics.bio-ph]",,,"Anglais",,,"Non",
"692182c6-6925-4317-92b2-81966a4a3afd","20.500.12210/13","Autre communication scientifique (congrès sans actes - poster - séminaire...)||Communication dans un congrès avec actes","10.1016/j.pdpdt.2017.01.170",,"Illumination profile characterization of a light applicator","Mordon, Serge||Munck, C.||Betrouni, N.","IPA",,"NANCY","France","2016-10-24",,,,,,"2017-03",,,,"Sciences du Vivant [q-bio]||Sciences du Vivant [q-bio]/Cancer",,,"Anglais","Oui","Internationale","Non",
"b5b31a98-bcc3-4c41-bcbe-0104dda14415","20.500.12210/13","Compte-rendu et recension critique d'ouvrage",,,"Red light photodynamic therapy for actinic keratosis using 37 J/cm 2 : fractionated irradiation with 12.3 mW/cm 2 after 30 minutes incubation time compared to standard continuous irradiation with 75 mW/cm 2 after three hours incubation time using a mathematical modeling","Vignion-Dewalle, Anne-Sophie||Baert, Grégory||Devos, Laura||Thecua, Elise||Vicentini, Claire||Mortier, Laurent||Mordon, Serge",,,,,,,"Lasers in Surgery and Medicine",,,"Wiley","2017-04-02","0196-8092",,,"Sciences du Vivant [q-bio]||Sciences du Vivant [q-bio]/Cancer",,"Photodynamic therapy (PDT) is an emerging treatment modality for various diseases, especially for dermatological conditions. Although the standard PDT protocol for the treatment of actinic keratoses in Europe has shown to be effective, treatment-associated pain is often observed in patients. Different modifications to this protocol attempted to decrease pain have been investigated. The decrease in fluence rate seems to be a promising solution. Moreover, it has been suggested that light fractionation significantly increases the efficacy of PDT. Based on a flexible light-emitting textile, the FLEXITHERALIGHT device specifically provides a fractionated illumination at a fluence rate more than six times lower than that of the standard protocol. In a recently completed clinical trial of PDT for the treatment of actinic keratosis, the non-inferiority of a protocol involving illumination with the FLEXITHERALIGHT device after a short incubation time and referred to as the FLEXITHERALIGHT protocol has been assessed compared to the standard protocol. In this paper, we propose a comparison of the two above mentioned 635 nm red light protocols with 37 J/cm 2 in the PDT treatment of actinic keratosis: the standard protocol and the FLEXITHERALIGHT one through a mathematical modeling, which slightly differs from the one we have already published. This comparison performed in terms of the local damage induced by the therapy demonstrates that the FLEXITHERALIGHT protocol with lower fluence rate, light fractionation and shorter incubation time is somewhat less efficient than the standard protocol. Nevertheless, from the clinical trial results, the FLEXITHERALIGHT protocol results in non-inferior response rates compared to the standard protocol. This finding raises the question of whether the PDT local damage achieved by the FLEXITHERALIGHT protocol (respectively, the standard protocol) is sufficient (respectively, excessive) to destroy 2 actinic keratosis cells…","Anglais",,,"Non",
"56cc0dc0-8454-40a0-a0b4-9b488906ad2b","20.500.12210/13","Autre communication scientifique (congrès sans actes - poster - séminaire...)||Communication dans un congrès avec actes",,,"Photodynamic therapy for actinic keratosis: a trend towards a decrease in irradiance without loss of efficacy for a better tolerability","Vignion-Dewalle, Anne-Sophie||Vicentini, Claire||Baert, Grégory||Thecua, Elise||Lecomte, Fabienne||Mortier, Laurent||Mordon, Serge","17th International Photodynamic Association World Congress",,"Cambridge, Massachusetts","Etats-Unis d'Amérique","2019-06-28",,,,,,,,,"Photodynamic therapy||actinic keratosis||Aktilite CL128||irradiance||complete response","Sciences du Vivant [q-bio]||Sciences du Vivant [q-bio]/Cancer||Sciences du Vivant [q-bio]/Ingénierie biomédicale||Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Dermatologie",,"Photodynamic therapy (PDT) is an established treatment for actinic keratosis (AK). The conventional approved PDT protocol in Europe (C-PDT) involves red-light photoactivation at irradiances higher than 60 mW/cm 2 , making the treatment painful. Several clinical studies have reported similar efficacy and better tolerability when using red-light photoactivation at lower irradiances. The aim of the study was to investigate whether there is a minimum irradiance threshold for red-light photoactivation above which there is no further improvement in efficacy. A photodiode sensor connected to a power meter was used to measure the irradiance delivered to 114 AKs on the scalp and forehead of 19 patients during C-PDT using the Aktilite CL 128 (Galderma SA, Switzerland). The widely ranging measured irradiances, resulting from the heterogeneous photoactivation over the treatment area provided by the Aktilite CL 128, were cross-referenced with the clinically evaluated complete responses (CR) at 3 months. The 66 AKs in CR at 3 months received an average irradiance of 30.9 mW/cm 2 (standard deviation: 16.7 mW/cm 2) compared to 33.3 mW/cm 2 (standard deviation: 17.9 mW/cm 2) for the 48 AKs in incomplete response. No significant effect of the irradiance on the CR at 3 months was found (odds ratio for a 6 mW/cm 2-unit change, 0.96; 95% confidence interval, 0.83 to 1.10; p=0.53). No minimum irradiance threshold could therefore be determined in the considered irradiance range. A red-light device enabling homogeneous irradiation at a lower irradiance than the Aktilite CL 128 may therefore provide similar efficacy and higher treatment tolerability than C-PDT.","Anglais","Oui","Internationale","Non",
"24795b25-a604-4270-b30f-32fbae769782","20.500.12210/13","Compte-rendu et recension critique d'ouvrage","10.1016/j.pdpdt.2017.03.002","28300723","Nuclear medicine for photodynamic therapy in cancer: planning, monitoring and nuclear PDT","Kharroubi Lakouas, Dris||Huglo, Damien||Mordon, Serge||Vermandel, Maximilien",,,,,,,"Photodiagnosis and Photodynamic Therapy",,"Epub ahead of print","Elsevier","2017","1572-1000",,"Photodynamic therapy||Oncology||PET||SPECT||5-Aminolevulinic acid||PPIX","Sciences du Vivant [q-bio]/Ingénierie biomédicale/Médecine nucléaire||Sciences du Vivant [q-bio]/Cancer||Sciences du Vivant [q-bio]/Ingénierie biomédicale",,"Photodynamic therapy (PDT) is a modality with promising results for the treatment of various cancers. PDT is increasingly included in the standard of care for different pathologies. This therapy relies on the effects of light delivered to photosensitized cells. At different stages of delivery, PDT requires imaging toplan, evaluate and monitor treatment. The contribution of molecular imaging in this context is important and continues to increase. In this article, we review the contribution of nuclear medicine imaging in oncology to PDT for planning and therapeutic monitoring purposes. Several solutions have been proposed to plan PDT from nuclear medicine imaging. For instance, photosensitizer biodistribution has been evaluated with aradiolabeled photosensitizer or with conventionalradiopharmaceuticals on positron emission tomography. The effects of PDT delivery have also been explored with specific SPECT or PET radiopharmaceuticals to evaluate the effects on cells (apoptosis, necrosis, proliferation, metabolism) or vascular damage. Finally, the synergy between photosensitizers and radiopharmaceuticals has been studied considering the Cerenkov effect to activate photosensitized cells.","Anglais",,,"Non",
"300c2a54-a915-42b4-bd79-7a77e7d45ce8","20.500.12210/13","Autre communication scientifique (congrès sans actes - poster - séminaire...)||Communication dans un congrès avec actes",,,"PDT in dermatology: quantification, relevance and comparison of light sources within a few clicks","Vignion-Dewalle, Anne-Sophie||Baert, Grégory||Thecua, Elise||Lecomte, Fabienne||Vicentini, Claire||Mortier, Laurent||Mordon, Serge","17th International Photodynamic Association World Congress",,"Boston Marriott Cambridge Cambridge, Massachusetts,","Etats-Unis d'Amérique","2019-06-28",,,,,,,,,"Photodynamic therapy||light sources||actinic keratoses||protoporphyrin IX||PpIX-weighted irradiance||website","Sciences du Vivant [q-bio]||Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Dermatologie||Sciences du Vivant [q-bio]/Cancer",,"Photodynamic therapy (PDT) for dermatological conditions relies on the photoactivation of the photosensitizer protoporphyrin IX (PpIX). Many light sources have been or are being investigated. The stronger the overlap of the spectral irradiance of the light source with the absorption spectrum of PpIX is, the more powerful to photoactivate PpIX is the light source. This overlap can be quantified using the PpIX-weighted irradiance, which results from the weighting of the spectral irradiance of the light source by the normalized PpIX absorption spectrum. We have previously developed a freely available website (http://www.oncothai.fr/light-efficiency-calculator/), which aims to compute the PpIX-weighted irradiance of any uploaded spectral irradiance. Through this website, we have assessed a variety of light sources proposed for use in dermatological PDT. The spectral irradiances of these light sources were collected either by extraction from the literature or request to manufacturers. Due to the variations in position, shape, and amplitude of the spectral irradiances with regard to the PpIX normalized absorption spectrum, a wide range of PpIX-weighted irradiances has been obtained. The maximal PpIX-weighted irradiance was achieved with daylight on a clear sunny day.","Anglais","Oui","Internationale","Non",
"6a00d1be-96e8-4464-a1a3-c51549622449","20.500.12210/13","Autre communication scientifique (congrès sans actes - poster - séminaire...)||Communication dans un congrès avec actes",,,"Light emitting fabrics for PDT: technology and results of clinical studies","Mordon, Serge||Thecua, Elise||Lecomte, Fabienne||Vignion-Dewalle, Anne||Deleporte, Pascal||Maire, Cyril||Abi-Rached, Henry||Vicentini, Claire||Hommel, Theresa||Szeimies, R||Mortier, Laurent","17th International Photodynamic Association World Congress",,"Cambridge, Massachusetts","Etats-Unis d'Amérique","2019-06-28",,,,,,,,,"Photodynamic Therapy||Light Emitting Fabric||Textile||Laser||Actinic Keratosis||Clinical Evaluation","Sciences du Vivant [q-bio]||Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Dermatologie||Sciences du Vivant [q-bio]/Cancer",,"A homogeneous and reproducible fluence rate delivery during clinical PDT plays a determinant role in preventing under-or overtreatment. In Dermatology, topical PDT has been carried out with a wide variety of light sources delivering a broad range of light doses. However, these light sources do not deliver a uniform light distribution on the skin due to their structure and morphology and the complexities of the human anatomy. The development of a flexible light source able to generate uniform light on all its surface would considerably improve the homogeneity of light delivery. The integration of plastic optical fibers (POF) into textile structures offers an interesting alternative. The homogeneous light side-emission from the fabric is obtained by controlling the bending angles of POF inside the LEF due to specific architecture generated by knitting of textile structure. LEF of different surfaces can be easily manufactured (up to 500cm² The LEF thickness is less than 1 mm. The mean irradiance is typically 2.5 mW.cm-².W-1 with heterogeneity of 12.5 % at any point of the LEF. The temperature elevation remains below 1°C. These LEF were evaluated in Dermatology for the treatment of Actinic Keratosis. Two clinical evaluation were performed. The first one was a monocentric, randomized, controlled, phase II clinical study (ClinicalTrials.gov Identifier: NCT03076918). Twenty five (25) patients with grade I-II actinic keratosis (AK) of the forehead and scalp were treated with methyl aminolevulinate photodynamic therapy in two symmetrical areas. One area was treated with the conventional LED panel (154 AK), whereas the other area was treated with the LEF device (156 AK). The second clinical was performed in 2 centers. This new LEF device was a more ergonomic and compact version of the original system developed for FLEXI-PDT. In this clinical study (ClinicalTrials.gov Identifier: NCT03076892), the irradiance has been reduced from 12.3 mW/cm 2 to 1.3 mW/cm 2 and the light dose from 37 J/cm 2 to 12 J/cm 2. Compared to Conventional PDT, the 2 protocols clearly shown that LEF are equivalent and even superior in terms of efficacy for treating AK of the forehead and scalp. However, the use of LEF resulted in much lower pain scores and fewer adverse effects. In conclusion, thanks to LEF, PDT of AK can be conducted in all weather conditions, in any geographic location, year-round and benefits from the optimal adaptability of the flexible, light-emitting, fabrics to the treatment area. At last, LEF can be easily can be easily manufactured in large series.","Anglais","Oui","Internationale","Non",
